Clinical practice guideline for Allied Hirschsprung’s diseases – Practical version

“Research for establishing guidelines for rare and intractable gastrointestinal diseases, spanning childhood to the transition phase” (Tomoaki Taguchi’s group)
Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in 2014 fiscal year
Issue date of first edition: June 4, 2017
# Table of contents

I. Introduction .................................................................................................................................................. 3

II. Guideline Summary ................................................................................................................................... 5

III. List of terminology and abbreviations ..................................................................................................... 9

IV. Development organization and policy ...................................................................................................... 11

1. Development body .................................................................................................................................... 11
   1) Guideline steering committee .................................................................................................................. 11
   2) Guideline development group ................................................................................................................ 11
   3) Systematic review team .......................................................................................................................... 12
   4) External evaluation committee member .................................................................................................. 12
   5) Administration office for the guideline development ............................................................................ 12

2. Development process .................................................................................................................................. 13
   1) Policy ....................................................................................................................................................... 13
   2) Precautions .............................................................................................................................................. 14
   3) Conflict of interest ................................................................................................................................. 14
   4) Funding for the development .................................................................................................................. 14

V. SCOPE ......................................................................................................................................................... 15

1. Basic characteristics of allied Hirschsprung's diseases ............................................................................. 15
   1) Clinical characteristics of allied Hirschsprung's diseases ................................................................. 15
   2) Epidemiological characteristics of allied Hirschsprung's diseases .................................................... 16
   3) Overall flow of clinical practice for each allied Hirschsprung's disease (per disease) ..................... 16

2. Coverage of the clinical practice guideline ............................................................................................... 40
   1) Within the scope of this guideline ......................................................................................................... 40
   2) Outside of the scope of this guideline ................................................................................................... 40

3. CQ and systematic review .......................................................................................................................... 40
   1) Setting of CQ ......................................................................................................................................... 40
   2) Systematic review ................................................................................................................................. 40

4. Determination of recommendations to finalization and implementation policy ........................................... 42
   1) Determination of recommendations .................................................................................................... 42
   2) Finalization ............................................................................................................................................ 43
   3) Implementation ..................................................................................................................................... 43

VI. Recommendation ....................................................................................................................................... 49

1. CQ1: How are isolated hypoganglionosis, MMIHS, CIIP diagnosed? .......................................................... 49

2. CQ2: What kind of drug therapy is recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP? ......................................................................................................................... 57

3. CQ3: Is gastrointestinal decompression therapy recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP? .............................................................................................................. 64
CQ4: Is nutrition therapy recommended for isolated hypoganglionosis, MMIHS, and CIIP? .................. 69
CQ5: Is radical surgical treatment recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?.................................................................................................................. 75
CQ6: Is small bowel transplantation recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?.................................................................................................................. 78
CQ7: What is the prognosis of isolated hypoganglionosis, MMIHS, and CIIP?................................. 84

VII. Planning after public release ........................................................................................................ 87
   1. Organization after public release .............................................................................................. 87
   2. Introduction ............................................................................................................................ 87
   3. Evaluation of effectiveness ...................................................................................................... 87
   4. Revision ................................................................................................................................. 88
I. Introduction

Despite the presence of ganglion cells in the rectum, some cases showing symptoms and findings similar to those of Hirschsprung's disease have been recognized among pediatric surgeons. Since Ravitch described such cases as “pseudo Hirschsprung's disease” in the Annals of Surgery in 1958, various descriptions have been used, such as Hirschsprung's disease-related disorders, variant Hirschsprung's disease, allied disorders of Hirschsprung's disease, and Hirschsprung's disease-related neuromuscular disorders of the intestine. However, the disease concepts and the individual diseases included in the disease group have changed gradually over time. In Japan, this group of disease was initially described as “aganglionosis-related disease” in Neonate Surgery in 1978, and in 1988, a survey report of allied Hirschsprung's diseases was released in the Journal of the Japanese Society of Pediatric Surgeons (Akihiro Toyosaka). In 1993, a national survey was conducted by a research group on allied Hirschsprung's disease (Eizo Okamoto).

The development of a clinical practice guideline for allied Hirschsprung's diseases was triggered by a nationwide survey included in the "Survey regarding the current situation of allied Hirschsprung's diseases and the development of guidelines for the diagnostic criteria" project supported by the Ministry of Health, Labour and Welfare of Japan (Tomoaki Taguchi's group), in fiscal year 2011. The disease concept, classification, diagnostic criteria, and classification of severity were determined by the "Comprehensive study and seamless guidelines on rare and intractable gastrointestinal disease from childhood" (Tomoaki Taguchi's group) in 2012-2013. The development of a clinical practice guideline for allied Hirschsprung's diseases was continued by the "Research for establishing guidelines for rare and intractable gastrointestinal diseases, spanning childhood to transition phase" (Tomoaki Taguchi's group) in 2014-2016, and the guideline has now been released. Pediatric surgeons, pediatricians, pathologists, and others repeatedly discussed the disease concept, classification, and how to treat chronic idiopathic intestinal pseudo-obstruction. With the participation of Dr. Atsushi Nakajima from the adult domain of the research group for chronic idiopathic intestinal pseudo-obstruction, guidelines spanning such diseases from childhood to adulthood were successfully released.

With the cooperation of many people, three of the seven known allied Hirschsprung's diseases isolated hypoganglionosis, megacystis-microcolon-intestinal hypoperistalsis syndrome, and chronic idiopathic intestinal pseudo-obstruction were officially certified as intractable diseases by the Ministry of Health, Labor and Welfare of Japan. We have had to employ unique methods to develop these clinical practice guideline, as high quality evidence is limited for these intractable diseases due to the few cases available for evaluation, the unknown etiology, and the lack of any established treatments. Fortunately, the doctors in Medical Information Network Distribution System (Minds) understood the situation and kindly provided careful guidance throughout the project. I sincerely appreciate the great support and efforts made by the systematic review team, who examined hundreds of domestic and international articles in detail in a short period of time, creating the evidence tables and Systematic Review reports by organizing the findings corresponding to each Clinical Question. This evidence table is now the core of this guideline,
and I hope it will serve as a useful document for clinical and research practice. Experts in the guideline development team created the recommendations in a short period of time. These efforts by the research members are greatly appreciated and were thoroughly vetted in external evaluation by Dr. Toshio Morizane. I hope that this clinical practice guideline will prove useful for both daily clinical practice as well as future studies.

I would like to pay my respect and show my gratitude to Dr. Tomoaki Taguchi for his strong leadership throughout this research project.

June 4, 2017
Development group for the clinical practice guidelines for allied Hirschsprung's diseases

Hiroshi Matsufuji
## II. Guideline Summary

### CQ1: How are isolated hypoganglionosis, MMIHS, and CIIP diagnosed?

<table>
<thead>
<tr>
<th>CQ1-1</th>
<th>How is isolated hypoganglionosis diagnosed?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>A full-thickness biopsy of the gastrointestinal tracts (especially the small intestine and sigmoid colon) is recommended for the definitive diagnosis of isolated hypoganglionosis. [1C]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ1-2</th>
<th>How is megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) diagnosed?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>For cases in which symptoms of bowel obstruction, such as abdominal distension and vomiting, are present during the neonatal period and no organic obstruction is observed, a gastrointestinal series is recommended. When a microcolon is observed and megalocystis is simultaneously confirmed by cystography or computed tomography (CT)/ultrasonography, MMIHS is strongly suspected. An intestinal full-thickness biopsy is recommended for the definitive diagnosis to differentiate it from other allied Hirschsprung’s diseases. [1C]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ1-3</th>
<th>How is chronic idiopathic intestinal pseudo-obstruction (CIIP) diagnosed?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>The duration of symptoms and the bowel obstruction conditions are determined from the clinical history and physical examination findings. The presence of intestinal dilatation, air-fluid level formation, and the absence of mechanical obstruction are confirmed by diagnostic imagings. For children, an intestinal full-thickness biopsy is recommended for the definitive diagnosis to differentiate it from other allied Hirschsprung’s diseases. For adults, it is important to differentiate true mechanical obstruction and secondary intestinal pseudo-obstruction, and a full-thickness biopsy is not conducted as it is for children. [1D]</td>
</tr>
</tbody>
</table>

### CQ2: What kind of drug therapy is recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?

<table>
<thead>
<tr>
<th>CQ2-1</th>
<th>What kind of drug therapy is recommended for the treatment of isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>No drug therapy for isolated hypoganglionosis is recommended at this point. [D]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ2-2</th>
<th>What kind of drug therapy is recommended for the treatment of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Although the usefulness of Chinese medicines (Daikenchuto) or probiotics has been reported as drug therapy for MMIHS, evidence is insufficient to recommend these therapies at present. [D]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ2-3</th>
<th>What kind of drug therapy is recommended for the treatment of chronic idiopathic intestinal pseudo-obstruction (CIIP)?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>As drug therapies for CIIP, prucalopride, cisapride, Chinese medicines (Daikenchuto), probiotics, and antibiotic (erythromycin) are sometimes used, and some reports have shown the usefulness of those agents for functional gastrointestinal disorder or abdominal symptoms. However, evidence is insufficient</td>
</tr>
</tbody>
</table>
to recommend these therapies at present. [D]

CQ3: **Is gastrointestinal decompression therapy recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?**

<table>
<thead>
<tr>
<th>CQ3-1</th>
<th>Is gastrointestinal decompression therapy recommended for the treatment of isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Upper jejunostomy is suggested for isolated hypoganglionosis. Ileostomy may be effective for some cases, but the effectiveness of enterostomies at any other part of the intestinal tract is unknown. [2C]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ3-2</th>
<th>Is gastrointestinal decompression therapy useful for the treatment of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>No evidence supports the positive recommendation of gastrointestinal decompression for MMIHS. [D]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ3-3</th>
<th>Is gastrointestinal decompression useful for the treatment of chronic idiopathic intestinal pseudo-obstruction (CIIP)?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Intermittent decompression via enteric tube may be effective in some CIIP cases, and enterostomy may be effective in other cases. The appropriate approach should be considered on a case-by-case basis. [2D]</td>
</tr>
</tbody>
</table>

CQ4: **Is nutritional therapy recommended for isolated hypoganglionosis, MMIHS, and CIIP?**

<table>
<thead>
<tr>
<th>CQ4-1</th>
<th>Are enteral nutrition and parenteral nutrition useful as nutritional therapies for isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Enteral nutrition and parenteral nutrition are recommended as nutritional therapies for isolated hypoganglionosis. [1D]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ4-2</th>
<th>Are enteral nutrition and parenteral nutrition useful as nutritional therapies for megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Enteral nutrition and parenteral nutrition are recommended as nutritional therapies for MMIHS. [1D]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CQ4-3</th>
<th>Are enteral nutrition and parenteral nutrition useful as nutritional therapies for chronic idiopathic intestinal pseudo-obstruction (CIIP)?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Enteral nutrition and parenteral nutrition are recommended as nutritional therapies for CIIP. [1D]</td>
</tr>
</tbody>
</table>

CQ5: **Is radical surgical treatment recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?**

<table>
<thead>
<tr>
<th>CQ5-1</th>
<th>Is radical surgical treatment (other than stoma construction) recommended for the treatment of isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation</strong></td>
<td>Avoiding radical surgical treatment is suggested. [2C]</td>
</tr>
</tbody>
</table>
### CQ5-2
**Is radical surgical treatment (other than stoma construction) recommended for the treatment of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?**

**Recommendation**
Resection of dilated intestines does not improve ileus symptoms in MMIHS, so avoiding radical surgical treatment is suggested. [2D]

---

### CQ5-3
**Is radical surgical treatment (other than stoma construction) recommended for the treatment of chronic idiopathic intestinal pseudo-obstruction (CIIP)?**

**Recommendation**
Concomitant use of antegrade continence enema and antidromic enema is suggested for the treatment of CIIP to improve defecation. [2D]
In cases with duodenal dilatation, duodenojejunostomy is suggested to improve the intestinal transit. It may relieve the pseudo-obstructive symptoms to some extent. [2D]
Intestinal resection dose not improve the pseudo-obstructive symptoms, so avoiding radical surgical treatment is suggested. [2D]

---

### CQ6: Is small bowel transplantation recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?

#### CQ6-1
**Is small bowel transplantation useful for the treatment of isolated hypoganglionosis?**

**Recommendation**
Small bowel transplantation is suggested for the treatment of isolated hypoganglionosis, as it may be useful for the following cases: patients in whom discontinuing parenteral nutrition (PN) is difficult even after the maximum use of the native intestinal tract under intestinal rehabilitation; patients in whom the number of central venous access routes is lacking; patients with repeated episodes of sepsis; and patients with progressive hepatopathy. [2D]

#### CQ6-2
**Is small bowel transplantation useful for the treatment of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?**

**Recommendation**
Isolated small bowel transplantation is suggested for cases not complicated with liver or renal failure. [2D]
Multiple organ transplantation is suggested for cases complicated with liver or renal failure. [2D]

#### CQ6-3
**Is small bowel transplantation useful for the treatment of chronic idiopathic intestinal pseudo-obstruction (CIIP)?**

**Recommendation**
Small bowel transplantation for the treatment of CIIP is suggested, as it may be useful for the following cases: patients whose symptoms remain intolerable even with adequate parenteral nutrition, enteral nutrition, and gastrointestinal decompression therapy; patients in whom the number of central venous access routes is lacking; and patients with repeated episodes of sepsis. The impaired native gastric outlet function needs to be considered when small bowel transplantation is planned and performed. [2D]

---

### CQ7: What is the prognosis of isolated hypoganglionosis, MMIHS, and CIIP?

#### CQ7-1
**What is the prognosis of isolated hypoganglionosis?**
**Recommendation**

A long-term survival can be expected with appropriate treatment. In many cases, adequate nutritional support and intestinal stoma care are required for a long period of time. [C]

---

<table>
<thead>
<tr>
<th>CQ7·2</th>
<th>What is the prognosis of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation</td>
<td>Patients with MMIHS have a poor prognosis compared to healthy children; however, a long-term survival can be expected with appropriate treatment. In many cases, adequate nutritional support and intestinal stoma care are required, and the functional prognosis is poorer than that of healthy children. [C]</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>CQ7·3</th>
<th>What is the prognosis of chronic idiopathic intestinal pseudo-obstruction (CIIP)?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation</td>
<td>The actual prognosis of CIIP developed in childhood is not poor; however, adequate nutritional support and intestinal stoma care are required for a long time in many cases. The functional prognosis of CIIP is poor. [C]</td>
</tr>
</tbody>
</table>
### III. List of terminology and abbreviations

<table>
<thead>
<tr>
<th>Terminology</th>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoganglionosis</td>
<td></td>
<td>A state of having a small number of intestinal ganglion cells. In Europe and the US, it may refer to the transitional zone of Hirschsprung’s disease.</td>
</tr>
<tr>
<td>Acetylcholinesterase staining</td>
<td>AchE staining</td>
<td>An enzymatic staining method. In the aganglionic intestine of Hirschsprung’s disease, positive nerve fibers can be seen to be growing with such staining.</td>
</tr>
<tr>
<td>Translational segment/transitional zone</td>
<td></td>
<td>Site between the aganglionic intestinal segment of Hirschsprung’s disease and the normal intestine. The number of ganglion cells is not sufficient in this zone. It may be described as “Hypoganglionosis”.</td>
</tr>
<tr>
<td>Pseudo-obstruction</td>
<td></td>
<td>A state of bowel obstruction without mechanical obstruction of the intestinal lumen.</td>
</tr>
<tr>
<td>Air-fluid level / niveau</td>
<td></td>
<td>An image seen with bowel obstruction, presented as a sharp flat horizontal line representing the interface between gas density above and fluid density below in the intestinal tract.</td>
</tr>
<tr>
<td>Megacystis-microcolon-intestinal hyperperistalsis syndrome</td>
<td>MMIHS</td>
<td>An allied Hirschsprung’s disease.</td>
</tr>
<tr>
<td>Clinical question</td>
<td>CQ</td>
<td>Clinically asked questions concerning various aspects of a disease, such as the condition, evaluation, treatment, risk, and prophylaxis. Organized by formulation with four elements (Patient, Intervention, Comparison, Outcome: PICO) to facilitate literature searches.</td>
</tr>
<tr>
<td>Enteral nutrition</td>
<td></td>
<td>A method of injecting liquid food and nourishing diet into the stomach or small intestine directly when food cannot be taken orally. Injected through a tube, gastrostomy, or enterostomy.</td>
</tr>
<tr>
<td>Systematic review</td>
<td>SR</td>
<td>A review using systematic and explicit methods to select and analyze collected data from high-quality studies, such as randomized controlled trials (RCTs).</td>
</tr>
<tr>
<td>Atresia of small bowel/small intestinal atresia</td>
<td></td>
<td>An intestinal blockage caused by a reduced blood supply due to volvulus or intussusception in the fetal stage.</td>
</tr>
<tr>
<td>Intestinal decompression</td>
<td></td>
<td>To drainage the gastrointestinal contents via enterostomy, gastrostomy, naso-gastric tube, long tube, or trans-anal tube in order to relieve intragastrointestinal pressure.</td>
</tr>
<tr>
<td>Manometry/intestinal manometric study</td>
<td></td>
<td>An examination to evaluate the presence of a normal pattern of intestinal motility by measuring the intragastrointestinal pressure. The object of the examination is to perceive the disease and its pathology and evaluate the motility function before and after surgical treatment.</td>
</tr>
<tr>
<td>Parenteral nutrition, intravenous alimentation</td>
<td></td>
<td>A technique providing nutrition intravenously. Intravenous nutrients are injected into a peripheral vein, higher-concentrated nutrients are directly infused into the central vein near the heart.</td>
</tr>
<tr>
<td>Neural ganglion/ neural plexus</td>
<td></td>
<td>A thick node where peripheral nerve cells and nerve fibers come together. In the intestinal tracts, it consists of multiple nerve cells and glia cells.</td>
</tr>
<tr>
<td>Stoma/intestinal stoma</td>
<td></td>
<td>An opening in the intestinal tract created on the abdominal wall to excrete stool due to intestinal tract disease.</td>
</tr>
<tr>
<td>Peristalsis</td>
<td></td>
<td>Movements of the intestinal tract made by contraction and relaxation of the smooth muscle. This movement mixes, breaks, and transfers the gastrointestinal contents (food).</td>
</tr>
<tr>
<td>Microcolon</td>
<td></td>
<td>Unused colon smaller in diameter and length than the normal colon. It is a consequence of a reduced colonic capacity due to congenital proximal intestinal obstruction and is different from structural abnormalities of the colon.</td>
</tr>
<tr>
<td>Intestinal ganglion cell/enteric ganglion cell</td>
<td></td>
<td>Nerve cells present in the intestinal tract. Multiple nerve (ganglion) cells form an intestinal neural ganglion (plexus).</td>
</tr>
<tr>
<td>Isolated hypoganglionosis</td>
<td>IND</td>
<td>An allied Hirschsprung’s disease. In such cases, the number of intestinal ganglion cells is small. To distinguish this disease from the transitional segment of Hirschsprung’s disease (hypoganglionosis), it is described as isolated hypoganglionosis.</td>
</tr>
<tr>
<td>Intestinal neuronal dysplasia</td>
<td></td>
<td>An allied Hirschsprung’s disease.</td>
</tr>
<tr>
<td>Segmental dilatation of intestine</td>
<td></td>
<td>An allied Hirschsprung’s disease.</td>
</tr>
<tr>
<td>Bowel obstruction</td>
<td></td>
<td>A state that consists of mechanical blockage of the intestinal lumen and functional blockage of the bowel stream (paralytic ileus) due to reduced peristalsis.</td>
</tr>
<tr>
<td>Recto-anal inhibitory reflex/recto anal reflex/recto internal anal sphincter inhibitory reflex</td>
<td>RAR/RAIR</td>
<td>A reflex response of relaxation of the internal anal sphincter followed by distention stimulation of the rectum. Patients with Hirschsprung’s disease lack the response.</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Rectal mucosal biopsy</td>
<td>An examination collecting a small part of the rectal mucosa for a pathological diagnosis. Acetylcholinesterase staining is used for the differentiation of Hirschsprung's disease.</td>
<td></td>
</tr>
<tr>
<td>Internal anal sphincter achalasia</td>
<td>An allied Hirschsprung's disease. The recto internal anal sphincter reflex is lacking, but ganglion cells exist in the rectum.</td>
<td></td>
</tr>
<tr>
<td>Aganglionosis</td>
<td>Used synonymously with Hirschsprung's disease. A state of lacking ganglion cells in the intestinal tract.</td>
<td></td>
</tr>
<tr>
<td>Bacterial translocation</td>
<td>A state in which enteric bacteria or bacterial products move across the intestinal membrane and emerge either in the lymphatics or the visceral circulation, causing infection. Sometimes observed when the intestinal mucosal defense system is ruined, when systemic and/or local immunity is compromised, or when intestinal bacterial overgrowth is present with motility disorder.</td>
<td></td>
</tr>
<tr>
<td>Hirschsprung's disease, congenital megacolon</td>
<td>Peristaltic disorders, bowel obstruction, and constipation are caused by the congenital absence of intestinal ganglion cells at the distal side of the intestinal tract. It is also called congenital megacolon, as the normal colon at the oral side of the aganglionic segment is dilated secondarily.</td>
<td></td>
</tr>
<tr>
<td>Allied Hirschsprung's disease</td>
<td>A group of diseases with conditions similar to Hirschsprung's diseases despite the presence of intestinal ganglion cells.</td>
<td></td>
</tr>
<tr>
<td>Immaturity of ganglia</td>
<td>An allied Hirschsprung's disease. Bowel obstructive symptom is evoked due to immature intestinal ganglion cells.</td>
<td></td>
</tr>
<tr>
<td>Chronic intestinal pseudo-obstruction</td>
<td>A generic term of pseudo-obstruction resulting in chronic course. It is categorized into &quot;primary&quot;, which has a cause in the intestinal tract itself, &quot;secondary&quot;, which is related to systemic illness or drugs, and &quot;idiopathic&quot; with an unknown etiology.</td>
<td></td>
</tr>
</tbody>
</table>
IV. Development organization and policy

1. Development body

“Research for establishing guidelines for rare and intractable gastrointestinal diseases, spanning childhood to the transition phase” (Tomoaki Taguchi’s group, Allied Hirschsprung’s disease group), Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in 2014 fiscal year

1) Guideline steering committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Department/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomoaki Taguchi</td>
<td>Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University</td>
</tr>
<tr>
<td>Tsuyoshi Tomomasa</td>
<td>PAL Children’s Clinic</td>
</tr>
<tr>
<td>Masaki Nio</td>
<td>Department of Pediatric Surgery, Tohoku University Graduate School of Medicine</td>
</tr>
<tr>
<td>Hiroshi Tamai</td>
<td>Department of Pediatrics, Osaka Medical College</td>
</tr>
<tr>
<td>Masanori Tamura</td>
<td>Department of Pediatrics, Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University</td>
</tr>
<tr>
<td>Haruhiko Sago</td>
<td>Department of Perinatal Medicine and Maternal Care, National Center for Child Health and Development</td>
</tr>
<tr>
<td>Akira Toki</td>
<td>Division of Pediatric Surgery, Department of Surgery, Showa University</td>
</tr>
<tr>
<td>Shunsuke Nosaka</td>
<td>Department of Radiology, National Center for Child Health and Development</td>
</tr>
<tr>
<td>Tatsuo Kuroda</td>
<td>Department of (Pediatric) Surgery, Keio University School of Medicine</td>
</tr>
<tr>
<td>Masahiro Yoshida</td>
<td>Chemotherapy Research institute, KAKEN Hospital</td>
</tr>
</tbody>
</table>

2) Guideline development group

<table>
<thead>
<tr>
<th>Name</th>
<th>Department/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hiroshi Matsufuji</td>
<td>Department of Pediatric Surgery, St Luke’s International Hospital</td>
</tr>
<tr>
<td>Atsushi Nakajima</td>
<td>Department of Gastroenterology and Hepatology, Yokohama City University</td>
</tr>
<tr>
<td>Hiroyuki Kobayashi</td>
<td>Department of Hospital Administration, Juntendo University</td>
</tr>
<tr>
<td>Hideki Sou</td>
<td>Department of Pediatric Surgery, Osaka Women’s and Children’s Hospital</td>
</tr>
<tr>
<td>Kouji Masumoto</td>
<td>Departments of Pediatric Surgery, Faculty of Medicine, University of Tsukuba</td>
</tr>
<tr>
<td>Yoshio Watanabe</td>
<td>Department of Pediatric Surgery, Aichi Children’s Health and Medical Center</td>
</tr>
<tr>
<td>Yutaka Kanamori</td>
<td>Division of Surgery, Department of Surgical Specialties, National Center for Child Health and Development</td>
</tr>
<tr>
<td>Yoshinori Hamada</td>
<td>Division of Pediatric Surgery, Department of Surgery, Kansai Medical</td>
</tr>
</tbody>
</table>
Atsuyuki Yamataka  
Department of Pediatric General and Urogenital Surgery, Juntendo University School of Medicine

Naoki Shimojima  
Department of Surgery, Tokyo Metropolitan Children's Medical Center

Tsuyoshi Tomomasa  
PAL Children’s Clinic

Akio Kubota  
Second Department of Surgery, Wakayama Medical University

Kosuke Ushijima  
Department of Pediatrics and Child Health, Kurume University School of Medicine

Ken Haruma  
General Internal medicine 2, General Medical Center, Kawasaki Medical School

Shin Fukudo  
Department of Behavioral Medicine, Tohoku University Graduate School of Medicine

3) Systematic review team

Yuko Araki  
Department of Pediatric Surgery, St Luke’s International Hospital

Takahiro Kudo  
Department of Pediatrics, Juntendo University Faculty of Medicine

Satoshi Obata  
Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University

Wataru Sumida  
Department of Pediatric Surgery, Aichi Children's Health and Medical Center

Toshihiko Watanabe  
Division of Surgery, Department of Surgical Specialties, National Center for Child Health and Development

Suguru Fukahori  
Department of Pediatric Surgery, Kurume University School of Medicine

Yoshimitsu Fujii  
Division of Pediatrics, Tohoku Medical and Pharmaceutical University

Yoshiyuki Yamada  
Division of Allergy and Immunology, Gunma Children's Medical Center

Keisuke Jimbo  
Department of Pediatrics, Juntendo University Faculty of Medicine

Fujimi Kawai  
St.Luke's International University Library

Tomoya Fukuoka  
Department of Pediatric Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children’s Hospital

Shinsuke Onuma  
Department of Pediatric Gastroenterology, Nutrition and Endocrinology, Osaka Women’s and Children’s Hospital

4) External evaluation committee member

Toshio Morizane  
Chief Visiting Researcher, Japan Council for Quality Health Care

5) Administration office for the guideline development

Satoshi Ieiri  
Department of Pediatric Surgery, Kagoshima University
2. Development process

1) Policy

Allied Hirschsprung's diseases consist of the following seven diseases: (1) immaturity of ganglia, (2) isolated hypoganglionosis, (3) intestinal neuronal dysplasia (IND), (4) megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), (5) segmental dilatation of intestine, (6) internal anal sphincter achalasia (IASA), and (7) chronic idiopathic intestinal pseudo-obstruction (CIIP). The guideline development committee members, as specialists in each disease, explained the basic characteristics of allied Hirschsprung's diseases overall and described each disease in detail. Since the pathological diagnosis plays the most important role in determining the clinical practice policy for allied Hirschsprung's diseases, a pathological approach segment was created.

Four allied Hirschsprung's diseases immaturity of ganglia, IND, segmental dilatation of intestine, and IASA show a good clinical course and are extremely rare; as such, these diseases are likely to rarely cause confusion when making therapeutic decisions in clinical practice.

Although the other three diseases isolated hypoganglionosis, MMIHS, and CIIP are also rare diseases, quite a few cases have been documented, and their clinical course is serious. These three diseases may therefore require the consideration of evidence and fair opinions from specialists when making decisions on their treatment in clinical practice. For these reasons, these three diseases were selected as targets of the clinical questions (CQs) of this guideline.

This guideline was developed using the methodologies in the "Minds Handbook for Clinical Practice Guideline Development 2014" and the "Minds Manual for Clinical Practice Guideline Development." However, as we expected difficulty in obtaining high-quality evidence on each disease, a unique approach was used for the systematic review. As the scope of the CQ includes intractable diseases, the opinions from the guideline development committee members, as specialists, are extremely important.
The committee members therefore held protracted discussions in order to prevent them from relying too heavily on their individual experiences, thereby helping them to build up a consensus.

2) Precautions
No clinical practice guideline for this group of diseases has yet been drafted. As many of the diseases in this group develop in childhood, clinical practice among pediatric patients was the focus in compiling this guideline. However, an increasing number of cases are enjoying a long-term survival due to recent progress in medicine; therefore, clinical practice for the transitional period from childhood to adulthood was also considered. Regarding clinical practice for CIIP that develops in adulthood, the “Clinical practice guideline for adults with chronic idiopathic intestinal pseudo-obstruction” (Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in 2011 fiscal year: Nakajima’s group) should be referenced.

3) Conflict of interest
There are no conflicts of interest to disclose among the stakeholders related to the development of this guideline.

4) Funding for the development
This guideline development was funded by the following research projects:

- “Survey regarding the current situation of allied Hirschsprung’s diseases and the development of guidelines for the diagnostic criteria” (Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in fiscal year 2011: Tomoaki Taguchi’s group)
- “Comprehensive study and seamless guidelines on rare and intractable gastrointestinal disease from childhood” (Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in fiscal years 2012-2013: Tomoaki Taguchi’s group)
V. SCOPE

1. Basic characteristics of allied Hirschsprung's diseases

1) Clinical characteristics of allied Hirschsprung's diseases

a. Background

Hirschsprung's disease is characterized by a transit disorder of intestinal content, delayed meconium excretion, abdominal distention, bilious vomiting, constipation, and intestinal dilatation (megacolon) at the proximal side, resulting from dyssynergy and a lack of a recto-anal reflex caused by aganglionosis of the intestinal tract at the distal side. In the field of pediatric surgery, this disease has been widely recognized, and the condition has been elucidated and appropriate therapy developed.

However, in this clinical and research setting, a group of diseases with similar symptoms and laboratory findings to Hirschsprung's disease despite the presence of ganglion cells in the rectum has also been recognized and is termed "allied Hirschsprung's disease" in Japan. The disease concept and diseases included in the group have changed over time, and a consensus has yet to be established among specialists.

A nationwide survey on the subject was conducted in the project of “Survey regarding the current situation of allied Hirschsprung's diseases and the development of guidelines for the diagnostic criteria” (Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in fiscal year 2011: Tomoaki Taguchi's group). In the next project, “Comprehensive study and seamless guidelines on rare and intractable gastrointestinal diseases from childhood” (Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in fiscal years 2012-2013: Tomoaki Taguchi’s group), specialists in pediatric surgery, pediatric gastrointestinal medicine, and adult gastrointestinal medicine determined the disease concept, classification, diagnostic criteria, and classification of severity. Subsequently, the development of a clinical guideline for allied Hirschsprung's disease was decided in the project of “Research for the establishing guidelines for rare and intractable gastrointestinal diseases, spanning childhood to the transition phase” (in fiscal years 2014-2016: Tomoaki Taguchi’s group).

b. Definition of allied Hirschsprung's diseases

Allied Hirschsprung's disease is a disease group characterized by symptoms and signs similar to those of Hirschsprung's disease, such as bowel obstruction, intestinal dilatation, and chronic constipation, despite the presence of ganglionic cells in the rectum.

c. Classification of allied Hirschsprung's diseases

The following seven diseases below are defined as allied Hirschsprung's disease, and are classified based on the pathological findings of intestinal nerves from hematoxylin and eosin (HE) or acetylcholinesterase (AchE) staining of the intestinal tract or rectal mucosa samples collected at surgery or a biopsy.
Diseases with abnormality in the intestinal ganglion cells
(1) Immaturity of ganglia
(2) Isolated hypoganglionosis
(3) Intestinal neuronal dysplasia (IND)
Diseases without abnormality in the intestinal ganglion cells (HE or AchE staining)
(4) Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)
(5) Segmental dilatation of intestine
(6) Internal anal sphincter achalasia (IASA)
(7) Chronic idiopathic intestinal pseudo-obstruction (CIIP)

2) Epidemiological characteristics of allied Hirschsprung's diseases
The table below shows the numbers of cases with allied Hirschsprung's diseases and the 10-year survival rates major pediatric medical institutions in Japan. Data were obtained in the project of “Survey regarding the current situation of allied Hirschsprung's diseases and the development of guidelines for the diagnostic criteria” in fiscal year 2011 (Tomoaki Taguchi’s group).

<table>
<thead>
<tr>
<th>Allied Hirschsprung's disease</th>
<th>Number of cases for the primary survey</th>
<th>Number of cases for the secondary survey</th>
<th>Number of definitive cases</th>
<th>Survival rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Abnormal ganglion cell group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Immaturity of ganglia</td>
<td>19</td>
<td>28</td>
<td>28</td>
<td>100%</td>
</tr>
<tr>
<td>(2) Isolated hypoganglionosis</td>
<td>114</td>
<td>90</td>
<td>70</td>
<td>78%</td>
</tr>
<tr>
<td>(3) Intestinal neuronal dysplasia</td>
<td>17</td>
<td>11</td>
<td>11</td>
<td>100%</td>
</tr>
<tr>
<td>● Normal ganglion cell group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(4) Megacystis-microcolon-intestinal hypoperistalsis syndrome</td>
<td>29</td>
<td>19</td>
<td>10</td>
<td>53%</td>
</tr>
<tr>
<td>(5) Segmental dilatation of intestine</td>
<td>35</td>
<td>28</td>
<td>27</td>
<td>96%</td>
</tr>
<tr>
<td>(6) Internal anal sphincter achalasia</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>100%</td>
</tr>
<tr>
<td>(7) Chronic idiopathic intestinal pseudo-obstruction</td>
<td>94</td>
<td>56</td>
<td>56</td>
<td>89%</td>
</tr>
</tbody>
</table>

3) Overall flow of clinical practice for each allied Hirschsprung's disease

Histopathology of allied Hirschsprung's disease
This disease group is not associated with aganglionosis, but its clinical symptoms and findings are similar to Hirschsprung's disease and include bowel obstructive symptoms such as abdominal distention, abdominal pain, bilious emesis, and dilatation of intestinal tracts; delayed meconium excretion; and constipation. For this reason, a histological evaluation plays an important role in the diagnosis of allied Hirschsprung's diseases. The histological evaluation of enteric ganglions, especially in neonates and infants, requires professional knowledge and experience.

The majority of neonatal ileus cases may result in emergent laparotomy, and some diseases in this group requiring a histological evaluation (isolated hypoganglionosis, immaturity of ganglia) must be distinguished from small bowel atresia and Hirschsprung's disease (aganglionosis).

Ideally, intestinal full-thickness biopsy samples should be collected at the three points indicated in the flow chart (Figure 1), with HE staining and immunohistological investigations used for the
histopathological diagnosis (Figures 2–4). Anti-HuC/D antibody has excellent sensitivity and specificity for identifying immature and small neurocytes of neonates and infants. Sox10 antibody positivity in intestinal glia cell nuclei is useful for differentiating immature neurocytes from intestinal glia cells. When the neural plexus is normal in size and ganglion cells are normal in number and size in samples obtained by full-thickness biopsies from the stoma site at the oral side sufficiently far from the caliber change and from the terminal ileum, Hirschsprung's disease should be diagnosed if hypertrophic acetylcholinesterase-positive nerve fibers in the lamina propria mucosae is observed in samples obtained by a rectal mucosal biopsy or if a lack of myenteric ganglion cells and nerve fascicle formations is observed in a sample obtained by a full-thickness biopsy from the sigmoid colon.

A useful indicator for the diagnosis of isolated hypoganglionosis is the presence of ≤20 HuC/D-positive cells per centimeter within the muscularis propria in a specimen from a resected intestinal tract, as this is a significantly lower number than that noted in normal intestinal tract.

For the diagnosis of immaturity of ganglia with immature neurocytes but no abnormal numbers, the final diagnosis should be made based on the absence of any abnormality in the nerve plexus or neurocytes at the time of stoma closure.
**Figure 1.** Histopathological differentiation of allied Hirschsprung's disease

![Diagram showing the differentiation process of Hirschsprung's disease](image1.png)

**Figure 2.** Normal Auerbach's myenteric plexus

Several matured ganglion cells are observed in the nerve plexus.
**Figure 3. Immaturity of ganglia, Auerbach's myenteric plexus**
The nerve plexus is normal in size, and ganglion cells are normal in number but small and immature.

**Figure 4. Isolated hypoganglionosis, Auerbach's myenteric plexus (arrow)**
The nerve plexus is small and, the number of ganglion cells is decreased.
(1) Immaturity of ganglia

**Disease concept:** Neonatal ileus symptoms present with a clinical manifestation similar to meconium disease. In a barium enema examination, narrowing of the colon is observed (microcolon or small colon). In the neonatal period, the recto-anal reflex is negative in many cases, but turns positive in infancy. A rectal mucosal biopsy can differentiate immaturity of ganglia from Hirschsprung's disease based on the lack of hypertrophic AchE-positive nerve fibers. As the lesion may extend to the small bowel, ileostomy is required in many cases during the neonatal period. On a pathological examination, the intramural ganglion cells are sufficient in number but are small and markedly immature. Neurocytes may mature in several months, and ileostomy closure can be performed. Both the vital and functional prognoses of this disease are good.

**Diagnostic criteria**

Primary diagnostic criteria

1) Develops during the neonatal period
2) Affected bowel may extend to the small bowel
3) Caliber change is observed during surgery

Secondary diagnostic criteria

1) Symptoms improve over time
2) On diagnostic imaging, microcolon or narrowing of the left hemicolon is present.

Pathological diagnostic criteria (1 and 2 or 1 and 3 need to be met)

1) Immature ganglion cells (small in size)
2) Normal number and distribution of ganglion cells
3) Ganglion cells mature over time

Isolated hypoganglionosis is diagnosed based on an indispensable pathological examination at enterostomy if two or more primary diagnostic criteria, or if one primary plus two secondary diagnostic criteria are met.

A nationwide survey followed 28 cases for 10 years from 2001 to 2010. The number of cases with definitive diagnoses meeting the above criteria (proposed) was 15, and all of them survived.
(2) Isolated hypoganglionosis

**Disease concept**: Isolated hypoganglionosis is a disease that causes serious functional bowel obstruction during the neonatal period or later, and is a congenital gastrointestinal disease with poor prognosis. In English, it is expressed as ‘isolated hypoganglionosis’ in order to distinguish it from the site with reduced neurocytes (transitional zone) observed between the aganglionic and normoganglionic segment in Hirschsprung’s disease.

Most cases require stoma (enterostomy) and parenteral nutrition for life support over a long period of time, and severe cases are potential candidates for small bowel transplantation. It is difficult to differentiate isolated hypoganglionosis from Hirschsprung’s disease by a barium enema examination or anorectal manometry.

An intestinal pathological examination shows that the intestinal nerve plexus is small with few ganglion cells. In this respect, it is difficult to differentiate the isolated hypoganglionic tract from the transition zone of Hirschsprung's disease between the aganglionic and normoganglionic tract. The individual ganglion cells in the whole intestinal tract are small in size during the neonatal period, but they grow over time as they mature, although their number will never increase. Isolated hypoganglionosis can be distinguished from Hirschsprung's disease in that it has no exogenous nerve fiber growth in the colon and no nerve fiber growth at the distal colon. Laparotomy is required to resolve bowel obstruction during the neonatal period. A definitive diagnosis can be made by a pathological examination with a full-thickness intestinal biopsy.

**Pathological diagnosis criteria**

In the neonatal period, Hirschsprung's disease can be ruled out using frozen section of full-thickness intestinal specimens collected from the jejunum or ileum (both if possible) and sigmoid colon. At the second laparotomy at two months of age, such as when changing a double-barrel fistula into a Bishop-Koop type fistula, permanent preparations of the entire intestinal circumference should be created to determine the decrease in ganglionic cell number.

**Severity criteria**

A severe case is defined as one whose daily life is significantly impaired due to bowel obstruction symptoms, such as abdominal distension, nausea and vomiting, and abdominal pain, and when at least one of the following three items is met:

1) Parenteral nutrition is required.
2) Enteral nutrition is required.
3) Continuous gastrointestinal decompression is required.\(^\text{Note1}\)

Note 1) Gastrointestinal decompression refers to the drainage of intestinal contents through enterostomy, gastrostomy, nasogastric tube, ileus tube, transanal tube, etc.
Basic clinical practice policy is to provide adequate nutrition via central venous parenteral nutrition and/or enteral nutrition and to perform appropriate decompression surgery in order to prevent congestive enteritis. Decompression necessarily requires enterostomy. The enterostomy site is important, as the first stoma site is a key factor in determining the treatment outcome of isolated hypoganglionosis. In the nationwide survey conducted in 2001-2010, cases that underwent jejunostomy at the first surgery had better outcomes than those with ileostomy. Regarding the appropriateness of resection of the functionally disordered intestinal tract at the anal side from enterostomy, the need for preservation may be suggested based on the outcome of the experimental treatments. Unfortunately, however, no cohort study has yet been conducted, so further studies are needed before any conclusions can be made. Severe cases can also be saved by organ transplantation, and future studies should examine the appropriateness of small bowel transplantation versus multiorgan transplantation for such patients.
(3) Intestinal Neuronal Dysplasia (IND)

**Disease concept:** In 1971, Meier-Ruge proposed this disease and classified it into types A and B. Type A is very rare, accounting for about 5% of IND, and presents with bowel obstruction, diarrhea, and bloody stool during the neonatal period. Reduction in intestinal sympathetic nervous system innervation is observed.

As type B can account for up to 95% of IND cases, this section focuses on type B. Blockage of the lower gastrointestinal tract similar to that with Hirschsprung's disease is observed. There are no characteristic findings on a barium enema examination except for dilatation of the rectosigmoid colon. Positive and negative cases are present on a recto anal reflex examination. As the morbidity rate depends on each institution, the diagnostic criteria and pathological investigation strategy need to be unified.

Pathologically, malformation of the intestinal parasympathetic nervous system is present. On AchE staining, submucosal giant ganglia, hyperganglionosis, ectopic ganglia, and growth of AchE-positive nerve fibers are observed (Figure 5). These conditions may exist independently, or they may be associated with intestinal segments with normal ganglion cells in Hirschsprung's disease or with anal atresia. Whether the pathological finding is a congenial change or a secondary change related to growth and development or to constipation remains controversial. Conservative therapies, such as laxatives or enema, can often control these conditions. If they are not improved by such therapies, resection of the internal anal sphincter is indicated. Intestinal resection may be required in rare cases.

**Diagnostic criteria**

The following three items need to be satisfied:

1) Symptoms similar to those of Hirschsprung's disease
2) Both:
   a) Presence of giant ganglia (≥9 neurocytes in 1 ganglion)
   b) Growth of AchE-positive nerve fibers
3) Neonates and infants excluded

Note) Neonatal and infant cases meeting the above 1) and 2) need to be strictly followed as suspected cases.

In a nationwide survey conducted over 10 years from 2001 to 2010, 8 definitive and 9 suspected cases were enrolled, with 11 cases confirmed as IND. The most common onset time was the neonatal period and infancy, followed by childhood. There have only been a few reports in Japan, and the disease may be included among cases diagnosed as chronic functional constipation.
**Figure 5. Intestinal Neuronal Dysplasia (IND)**

Acetylcholinesterase staining (left): Submucosal giant ganglia is observed.

HE staining (right): Many ganglion cells are observed in a large nerve plexus.
(4) Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)

**Disease concept:** A serious disease that presents as bowel obstruction-like symptoms in the neonatal period and later, resulting in intestinal failure, which is accompanied by megalocystis and microcolon. Many such cases require gastrointestinal decompression via gastrostomy or intestinal stoma during neonatal period. In a pathological examination, no abnormality is observed in the intestinal nerve plexus.

### Diagnostic criteria

1) Bowel obstruction symptoms such as abdominal distension, vomiting, and abdominal pain present immediately after birth
2) Megacystis present
3) Barium enema reveals microcolon in the neonatal period *(Figure 6)*
4) No mechanical obstructive lesion observed in the gastrointestinal tract
5) No pathological abnormality observed in the neural plexus in specimen with a full-thickness intestinal biopsy

### Severity criteria

A severe case is defined as one whose daily life is significantly impaired due to bowel obstructive symptoms, such as abdominal distension, nausea, vomiting, and abdominal pain, and when at least one of the following three items is met:

1) Parenteral nutrition is required
2) Enteral nutrition is required
3) Continuous gastrointestinal decompression is required

Note 1) Gastrointestinal decompression refers to the drainage of intestinal contents through enterostomy, gastrostomy, nasogastric tube, ileus tube, transanal tube, etc.

A nationwide survey conducted over 10 years from 2001 to 2010 enrolled 19 definitive and 5 suspected cases. Enterostomy was performed for 16 out of the 19 definitive cases for decompression.

Due to intestinal failure, parenteral nutrition or enteral nutrition needs to be used for a long period of time. Four out of the 19 cases needed total parenteral nutrition, and 12 needed concomitant use of parenteral nutrition and enteral nutrition. Seven out of the 9 surviving cases required parenteral nutrition. For this reason, serious complications, such as hepatic disorder, catheter-related bloodstream infection, enteritis, and bacterial translocation, can easily occur with this disease.

Ten out of the 19 cases survived, and 9 cases died, with a 5-year survival rate of 62.8% and 10-year rate of 56.5%. The main causes of death were hepatic disorder and sepsis.
Figure 6  Barium enema image of MMIHS

Microcolon is observed.
(5) Segmental Dilatation of Intestine

**Disease concept**: Segmental dilatation of the intestine is a rare disease that presents with localized dilatation of intestines without mechanical bowel obstruction and malformation of the intestinal nerve plexus. Since Swenson and Rathauser reported this disease as a "new entity" in 1959, various causes have been discussed; however, the clinical manifestation and pathological findings vary, and the disease concept has never been determined in a simple manner. It may therefore be appropriate to regard it as a group of diseases that presents with localized intestinal dilatation.

### Diagnostic criteria

This disease is diagnosed when the following six items are met:

1. Intestinal tract segmentally (permanently) dilated
2. Normal intestinal segment abruptly transitions to a dilated segment
3. No endogenous or exogenous cause of obstruction noted at the anal side of the dilated segment
4. Complete or partial bowel obstruction observed on diagnostic imaging
5. Normal distribution of the nerve plexus on a pathological examination
6. Resection of the lesion improves symptoms

### Severity classification

If this disease is not complicated by any other diseases, resection of the lesion significantly improves the symptoms. The prognosis is good, and severity classification may be unnecessary.

**Clinical manifestation**: In Japan, although about 50 cases have been reported in the literature, no large-scale survey has been conducted in the past. A nationwide survey conducted over 10 years from 2001 to 2010 identified 37 cases, including 26 definitive and 9 suspected cases. Based on a secondary survey of these cases, 28 were determined as definitive cases by adding 2 of the suspected cases, after discussions at investigation group meetings and general meetings.

**Gender**: Regarding the 28 cases, 19 (68%) were boys and 9 (32%) were girls. Boys were more likely to present with this disease than girls.

**Gestational week and birth weight**: The gestational week was 30.2 weeks on average, with 7 cases (25%) of preterm deliveries. The average birth weight was 2,319 g. The number of low-birth-weight infants was 9 (32%), including 1 very-low-birth-weight infant and 2 extremely-low-birth-weight infants.

**Chromosome aberration**: Two cases (7.1%) of trisomy 21 was observed.

**Family history**: The majority (26 cases) had no family history, while 2 had a history. In one case, four cousins on the mother's side had segmental dilatation of the colon, and one of them died. The other case showed marked constipation.

**Combined malformation**: Seen in 7 cases out of 28 cases. Two cases had patent ductus arteriosus (PDA), and the remaining five cases had the following malformations (one each): Fallot's tetralogy, ventricular septal defect (VSD), cerebral palsy/clopocephaly/mandibular hypoplasia/low-set ears, FG syndrome,
Fallot’s tetralogy/encephalatrophy/scoliosi/cleft lip and palate/low-set ears/horseshoe kidney/right hydronephrosis/hypospadias.

**Gastrointestinal tract complications**: Four out of 28 cases had complications, including 2 cases (7.1%) of malrotation, 1 case (3.5%) of ileal atresia, and 1 case (3.5%) of anal atresia.

**Dilatation sites**: Ileum was the most common (14 cases, 50%) site, followed by sigmoid colon (5 cases, 18%), jejunum (3 cases, 11%), transverse colon (3 cases, 11%), from the cecum to transverse colon (1 case), cecum (1 case), and duodenum (1 case).

**Onset time**: The neonatal period (18 cases, 64%) was the most common, and with the frequency decreasing with increasing age as follows: infancy (6 cases, 21%), childhood (2 cases, 7.1%), and school age or later (2 cases, 7.1%).

**Initial symptom**: Abdominal distension (20 cases, 71%), vomiting (13 cases, 46%), abnormality noted on a prenatal diagnosis (7 cases, 25%), chronic constipation (6 cases, 21%), and delayed meconium excretion (4 cases, 14%). One case had strangulated ileus due to midgut volvulus, and another had intestinal perforation.

**Examination findings**: Twenty-five cases (89%) showed abnormal dilatation of the intestine on plain abdominal X-ray. A barium enema examination was performed for 23 cases, of which 12 (52%) were diagnosed with segmental dilatation of intestine. Seven cases (25%) were found to have intestinal dilatation by ultrasonography or magnetic resonance imaging (MRI) in the prenatal period. The rectoanal reflex was positive in all seven examined cases, and no increase in acetylcholinesterase-positive nerve fibers was seen in any of the five cases in which a rectal mucosal biopsy were performed.

**Diagnosis**: Plain abdominal radiography successfully indicated the presence of the lesion in many cases ([Figure 7](#fig7)). A preoperative diagnosis also requires confirmation of the segmental intestinal dilatation by contrast radiography or computerized tomography (CT). When the dilatation site is in the colon, it needs to be differentiated from Hirschsprung's disease. A caliber change should be observed clearly at the oral side of the dilated segment by barium enema for this disease. If it is not clear, anorectal manometry or a rectal mucosal biopsy is required for the differentiation.

**Treatment**: Resection of the dilated segment ([Figure 8](#fig8)) and end-to-end anastomosis of the intestine will provide a good prognosis. Surgery was performed in 27 cases, and 1 case was waiting for surgery. Laparotomy was performed for the resection of the dilated segment and intestinal anastomosis in 26 cases out of 27 cases. For 1 case, segmental dilatation of intestine (SD) was detected during the surgery for malrotation, and the patient was followed up without resection. However, the dilatation persisted, and it was resected after the survey. Out of the 26 cases in which resection of dilated segment and intestinal anastomosis were performed, enterostomy was created in 4 cases, and gastrostomy was created in 2 cases. Surgery was performed during the neonatal period in 13 cases (48%), infancy in 4 cases (15%), childhood in 5 cases (19%), and school-age in 3 cases (11%).

**Prognosis**: A total of 27 cases are surviving with a good prognosis. One patient died: a 9-year-old boy with cerebral palsy who had segmental dilatation in the cecum. Ileocecral resection was performed, but he died
of sepsis, hepatic disorder, and catheter infection at 12 years of age. A necrotic change was observed in a resected specimen.

**Figure 7. Plain abdominal X ray of segmental dilatation of intestine**

Seven months of age. Marked intestinal dilatation and air-fluid level are observed.

**Figure 8. Resected dilated intestinal segment**
(6) Internal Anal Sphincter Achalasia (IASA)

**Disease concept**: IASA is a disease that shows intractable constipation due to relaxation failure of the internal anal sphincter despite the presence of ganglion cells in the rectal wall. This disease has been reported to account for 4.5% of chronic constipation in childhood and may be incorrectly diagnosed as chronic functional constipation. Regarding the treatment, in addition to medication, resection of the internal anal sphincter and botulinum toxin injection are performed. The prognosis of this disease is very good.

**Diagnostic criteria**

1) Refractory constipation present

2) No narrowing of the rectum observed under contrast enema

3) Negative recto anal reflex

4) Ganglion cells present in the specimen from a rectal mucosal biopsy

(Notes on diagnosis)

- The recto anal reflex should be evaluated with definite stimulation of the rectum after emptying the rectal contents, and the absence of a relaxation response of the internal anal sphincter should be confirmed.
- The status of AchE-positive nerve fibers should be checked when possible.

A total of 6 cases, including 3 cases in the primary nationwide survey conducted over 10 years from 2001 to 2010 and an additional 3 cases, were enrolled, and 2 met the above diagnostic criteria.
(7) Chronic Idiopathic Intestinal Pseudo-obstruction (CIIP)

**Disease concept:** CIIP is an intractable disease with unknown etiology that presents with prolonged bowel obstructive symptoms, such as abdominal distension, nausea and vomiting, and abdominal pain. Dilated bowel and air-fluid levels are shown on radiological examinations.

Chronic intestinal pseudo-obstruction (CIPO) is defined as functional motility disorder, presenting obstructive symptoms without mechanical obstruction to prevent the transportation of the gastrointestinal contents. CIPO is classified into three types: primary type, caused by gastrointestinal lesions; secondary type, associated with systemic illness or drugs; and idiopathic type with unknown etiology.

As the primary type includes Hirschsprung’s disease (aganglionosis) and allied Hirschsprung’s diseases (except CIIP), a diagnosis of childhood CIIP requires differentiation from these diseases. In the diagnosis of adult CIIP, it is important to differentiate secondary CIPO. In the adult domain, this disease remains recognized not only among general clinicians but even by medical practitioners specializing in the gastrointestinal. Inappropriate clinical practices and unrequired surgeries for the bowel obstructive conditions have been performed. Under these circumstances, “Clinical practice guideline for chronic intestinal pseudo-obstruction” (Research Project on Measures for Intractable Diseases, Health Labour Sciences Research Grant in fiscal year 2011: Nakajima’s group) was released publicly. In contrast, in the child domain, there are many neonatal-onset cases, and the disease is recognized as an allied Hirschsprung’s disease. This chapter mainly describes CIIP that develops in childhood.

**Definition:** CIIP is an intractable disease with unknown etiology, that presents with bowel obstructive symptoms, such as abdominal distension, nausea and vomiting, abdominal pain, and intestinal dilatation, due to gastrointestinal motility disorder despite the absence of anatomical obstruction.

**Diagnostic criteria**

The following 7 items need to be satisfied:

1) Persistent or repetitive development over a long period of time of serious bowel obstructive symptoms that may require hospitalization, such as abdominal distension, nausea and vomiting, abdominal pain, etc.

2) Duration of symptoms is $\geq 2$ months for neonatal onset and $\geq 6$ months for onset in infancy or later

3) Gastrointestinal dilatation and air-fluid level noted on diagnostic imaging

4) No lesions mechanically blocking the gastrointestinal tract

5) No pathological abnormalities in the nerve plexuses on HE staining obtained by an intestinal full-thickness biopsy

6) Megacystis-microcolon-intestinal hypoperistalsis syndrome and segmental dilatation of intestine excluded

7) Secondary chronic intestinal pseudo-obstruction excluded

Note 1) Confirmation of the air-fluid level on plain abdominal radiography in a standing position is not
necessarily required for neonates.

Note 2) For adults, when an intestinal full-thickness biopsy is unobtainable, a characteristic peristalsis disorder should be confirmed by manometry or cine MRI.

Note 3) Table 1 shows the secondary chronic intestinal pseudo-obstructions to be excluded.

### Severity criteria

Severe case is defined as one whose daily life is significantly impaired due to bowel obstructive symptoms, such as abdominal distension, nausea and vomiting, and abdominal pain, and when at least one of the following three items is met:

1) Parenteral nutrition is required.
2) Enteral nutrition is required.
3) Continuous gastrointestinal decompression is required.  

Note 1) Gastrointestinal decompression refers to the drainage of intestinal contents through enterostomy, gastrostomy, nasogastric tube, ileus tube, transanal tube, etc.

### Table 1. Secondary chronic intestinal pseudo-obstruction

1) Gastrointestinal smooth muscle-related diseases
   - Systemic sclerosis
   - Dermatomyositis
   - Multiple myositis
   - Systemic lupus erythematosus
   - Mixed connective tissue disease (MCTD)
   - Ehlers-Danlos syndrome
   - Muscular dystrophy
   - Amyloidosis
   - Small bowel-based lymphoid infiltration
   - Brown bowel syndrome (Ceroidosis)
   - Mitochondrial encephalomyopathy

2) Gastrointestinal nerves-related diseases
   - Familial dysautonomia
   - Primary dysautonomia
   - Diabetic neuropathy
   - Myotonic dystrophy
   - Pseudo-obstruction after infection, such as EB virus, Herpes Zoster virus, and Rota virus

3) Endocrine diseases
   - Hypothyroidism
   - Hypoparathyroidism
   - Phaeochromocytoma

4) Metabolic diseases
   - Uremia
   - Porphyria
   - Serious electrolytes abnormality (K⁺, Ca²⁺, Mg²⁺)

5) Others
Celiac disease
Kawasaki disease
Eosinophilic enteritis
Paraneoplastic pseudo-obstruction
Mesenteric vein thrombosis
Side reactions to radiotherapy
Angioedema
Intestinal tuberculosis
Crohn's disease
Chagas disease
Paralytic ileus resulting from injury, after gastrointestinal surgery, intraperitoneal inflammation, etc.
Ogilvie syndrome

6) Drug-induced diseases
Antidepressant
Antianxiety drug
Anthraquinone-based laxative
Phenothiazine drugs
Vinca alkaloid
Anticholinergic drug
Opioid
Ca channel blocker
Verapamil

Clinical manifestation: In a nationwide survey conducted over 10 years from 2001 to 2010, the number of primary enrollments of childhood-onset CIPO was 92, of which 90% or more were idiopathic. Among these, 56 cases met the diagnostic criteria of CIIP. This disease may sporadically develop, and peristalsis disorders may occur at any sites or multiple sites of the gastrointestinal tract. Lesion sites (dilated intestines) are frequently observed in the small bowel and the colon (Figures 9, 10).

Symptoms: The major initial symptoms are abdominal distension and vomiting for neonatal and infant-onset cases, and abdominal distension, vomiting, constipation, and diarrhea for older children. Adult cases may often present with abdominal pain. In some cases suffering from long-lasting pseudo-obstructive symptoms, gastrointestinal resting may relieve the symptoms. However, in the majority of cases, remission and exacerbation may be repeated with progressing conditions.

Flow of clinical practices: CIIP is likely to develop in the neonatal period or infancy, with bowel obstructive symptoms requiring emergent operations for the diagnosis and treatment; older children may often show gradual progress of their condition. Neonatal and infant-onset cases require differentiation from Hirschsprung's disease, isolated hypoganglionosis, megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), and segmental dilatation of intestine. For this reason, an intestinal full-thickness biopsy on laparotomy and gastrointestinal decompression with enterostomy are attempted early after the onset in most cases.

For cases with an onset in older childhood and adulthood, when an intestinal full-thickness biopsy is unobtainable, alternatively, a characteristic peristalsis disorder is checked for by cine MRI or manometry
(Figures 11, 12). It is also important to differentiate the disease from mechanical bowel obstruction and secondary intestinal pseudo-obstruction (Table 1). We herein report the diagnostic diagrams for child and adult CIIP (Figures 13, 14).

Many cases progress gradually, with repeating remission and exacerbation. Treatment may start with conservative treatments, such as drug therapy and intravenous/enteral nutrition, and then shift to invasive treatments, such as decompression by tubing or enterostomy, as the condition progresses. Intestinal perforation, necrosis, and severe enteritis indicate surgical treatments. Even after enterostomy and resection of dilated segments, obstructive symptoms may relapse due to dysfunction in the remaining intestines in many cases. Thus, multiple surgeries, such as exploratory laparotomy, enterostomy, intestinal resection, and enterostomy closure may be performed in some cases. In a few cases, small bowel transplantation may be performed when these conservative treatments become ineffective due to complications or when patients have suffered from intolerable pain for a long period of time (Figure 15).

**Prognosis:** Although the prognosis is relatively good, repeated long-term hospitalization is needed. Even for outpatient cases, intravenous/enteral nutrition support, and enterostomy managements may significantly limit their daily life. When gastrointestinal decompression is not effective, intestinal perforation or enteritis may lead to sepsis, resulting in death.

A total of 53 (94.2%) out of 56 cases that met the diagnostic criteria are surviving for a long term, but just a small part of them improved their conditions. The average duration of symptoms is 14.6 years, and the number of cases transitioning to adulthood CIIP is increasing. Nearly half of cases need gastrointestinal decompression via gastrostomy, enterostomy, or tubing. Furthermore, 74% of cases need some nutritional support, such as parenteral nutrition and/or enteral nutrition.
**Figure 9**  Plain abdominal X-ray of neonatal-onset CIIP
At day 8 after birth (left) and 4 months of age (right), intestinal dilatation is observed. No air-fluid levels are observed due to imaging in the prone position.

**Figure 10**  Plain abdominal X-ray of older childhood-onset CIIP
At 7 years of age (left), intestinal dilatation and air-fluid levels were present. At 17 years of age (right), the dilatation had progressed, and free air was observed under the diaphragm.
**Figure 11. Cine MRI of chronic idiopathic intestinal pseudo-obstruction**

Peristalsis is evaluated by continuously regenerating 30 images obtained by about 15-second continuous shooting of the organ. Selecting a specific site (circle) to graphically show the temporal change in the diameter of the intestine is useful for a peristaltic evaluation. In healthy subjects, the diameter of the intestinal tract changes over time, with repeated contractions observed (a, c). In CIIP patients, the diameter of the intestinal tract hardly changes over time, and contractions are not noted (b, d).

![Cine MRI images](image_url)

- **T=0s**
- **T=5s**
- **T=10s**
- **T=15s**

(a) Healthy subject: No morbid dilatation of the small bowel is observed, and active intestinal peristalsis is maintained.

(b) CIIP patient: Morbid dilatation of the small bowel is present with a marked decrease in peristalsis.

![Graphs of intestinal tract diameter and rate of contraction](image_url)

- **c) Healthy cases**
- **d) CIIP cases**
**Figure 12. Small bowel manometry for chronic idiopathic intestinal pseudo-obstruction**

For the accurate evaluation of CIIP, an investigation of the abnormality in the small bowel motility is important. After inserting a pressure transducer catheter nasally into the small bowel, the motility is measured over 24 h.

Upper: Oral side, Middle: Anal side by 5 cm, Lower: Anal side by 10 cm. Horizontal axis: Time (5-minute interval scale), Vertical axis: Pressure (mmHg).

In healthy subjects, the interdigestive small bowel motility and postprandial small bowel motility can be easily distinguished. Interdigestive small bowel motility consists of phase I with no contractions, phase II with irregular contractions, and phase III in which 11 to 12 tetanic contractions per minute, and these phases in this order are repeated periodically. Postprandial small bowel motility is induced with eating and is characterized by irregular contractions. The absence of a normal small bowel motility pattern was confirmed during the daytime with a CIIP patient shown below (a). Nighttime is suitable for evaluating the interdigestive small bowel motility, as the interdigestive time is longest between dinner and breakfast for the typical person, and agitation of the central nervous system may not easily influence the gastrointestinal tract. Normally, the characteristic phase III that occurs periodically is observed during the nighttime. However, phase III was not noted, and the absence of a normal small bowel motility pattern was confirmed while sleeping at night in the CIIP patient shown below (b).

![Graph (Daytime)](image)
a) CIIP case (Daytime)

![Graph (Nighttime)](image)
b) CIIP case (Nighttime)
Figure 13. Diagnostic flowchart for pediatric chronic idiopathic intestinal pseudo-obstruction

Bowel obstructive symptoms persists, and intestinal dilatation and air-fluid levels are observed on plain abdominal X-ray, CT, MRI, etc.

- **Mechanical obstruction**
  - **(+) ->** Bowel obstruction, bowel atresia

- **Any systemic diseases, or drugs that may cause gastrointestinal function disorder**
  - **(+) ->** Secondary intestinal pseudo-obstruction

- **Hypertrophic AchE-positive nerve fibers in rectal mucosal biopsy**
  - **(+) ->** Hirschsprung’s disease, NID

- **Presents Megacystis, microcolon Localized intestinal dilatation**
  - **(+) ->** Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) Segmental dilatation of intestine

- **Presents histopathological abnormalities in the intramural ganglion cells on HE staining with full-thickness intestinal biopsy**
  - **(+) ->** Isolated hypoganglionosis Immaturity of ganglia

**Chronic idiopathic intestinal pseudo-obstruction**
Figure 14. Diagnostic flowchart for chronic idiopathic intestinal pseudo-obstruction (for older children and adults)

Figure 15. Treatment flowchart for chronic idiopathic intestinal pseudo-obstruction
2. Coverage of the clinical practice guideline

1) Within the scope of this guideline
   a. All allied Hirschsprung's diseases
   b. Diagnoses for patients suspected of being in this disease group
   c. Clinical history, physical findings, diagnostic imaging, histopathology for this disease group
   d. Treatment for patients with a definitive diagnosis of this disease
   e. Medications, enteral nutrition, parenteral nutrition, various gastrointestinal decompression methods, surgical treatment, and transplantation for this disease group
   f. Vital and functional prognoses for each disease

2) Outside of the scope of this guideline
   a. Hirschsprung's disease (aganglionosis)
   b. Primary intestinal pseudo-obstruction not included in this disease group
   c. Secondary intestinal pseudo-obstruction

3. CQ and systematic review

1) Setting of CQ
   Four allied Hirschsprun’s diseases—immaturity of ganglia, IND, segmental dilatation of intestine, and IASA—show a good clinical course and are extremely rare; as such, these diseases are likely to rarely cause confusion when making therapeutic decisions in clinical practice.

   Although the other three diseases—isolated hypoganglionosis, MMIHS, and CIIP—are also rare diseases, quite a few cases have been documented, and their clinical course is serious. These three diseases may therefore require the consideration of evidence and fair opinions from specialists when making decisions on their treatment clinical practice. For these reasons, these three diseases were selected as targets of the clinical questions (CQs) of this guideline.

   The following seven CQs were created, and the recommendations are posed individually for the three diseases.

2) Systematic review

   CQ1: How are isolated hypoganglionosis, MMIHS, and CIIP diagnosed?
   CQ2: What kind of drug therapy is recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?
   CQ3: Is gastrointestinal decompression therapy recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?
   CQ4: Is nutritional therapy recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?
   CQ5: Is (radical) surgical treatment recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?
   CQ6: Is small bowel transplantation recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?
   CQ7: What is the prognosis of isolated hypoganglionosis, MMIHS, and CIIP?
This guideline was developed using the methodologies in the "Minds Handbook for Clinical Practice Guideline Development 2014" and the "Minds Manual for Clinical Practice Guideline Development." However, as we expected difficulty in obtaining high-quality evidence on each disease, a unique approach was used for the systematic review.

There are only a few reports on the rare diseases in the CQs, so sometimes the three diseases were duplicated or confused in a single paper. In addition, a scoping search showed that a majority of the articles were case reports. Many of the case reports have descriptions on the diagnosis, treatment, prognosis, and complications. For these reasons, we decided that the search would be conducted not by each CQ but by three diseases collectively, and the outcomes should then be assigned to each CQ.

The databases used were PubMed and Ichushi-Web, the languages in the scope were Japanese and English, and search date was unlimited. A total of 1,477 articles were obtained, and 3 members of our group conducted primary screening, ultimately selecting 396 articles for secondary screening (Tables 2, 3). Secondary screening by 10 members resulted in dropping 108 articles, and the evidence table was developed based on the remaining 288 articles.

In the creation of the evidence table, when one article was applicable to two or more CQs, extra rows were set accordingly, and the applicable outcomes and conclusions were recorded. The completed evidence table was summarized by each CQ, and a "Summary by CQ" was created. The SR team then made systematic review reports by each CQ.

(1) Overview of the systematic review

Decisions prior to the literature search

- Database used: PubMed and Ichushi-Web (Ichushi)
- Published year of literature in scope: All articles published through 2015
- Search conditions of literature: Only humans used as research subjects
- Language: Japanese and English
- Diseases in scope: Three allied Hirschsprung’s diseases (isolated hypoganglionosis, MMIHS, and CIIP)

Overview of the literature search

- Search by: Two members of the SR team (working independently)
- Search formula: Refer to the materials (Database search results: Tables 2, 3, Literature search flowchart: Figure 16).
- Number of articles: 1,488 (PubMed: 1,011 + Ichushi: 477)

(2) Primary screening

- Personnel in charge: Three members of the SR team
- Screening method: The above-mentioned 3 members independently checked the titles and abstracts of 1488 articles. At this stage, articles clearly unrelated to the predetermined CQs were excluded. Articles
for which the contents could not be judged based only on the title and abstract were included for review.

Primary screening result: After comparing the results from the 3 members, 396 out of 1,488 articles were ultimately selected for secondary screening.

(3) Secondary screening and creation of evidence table

Personnel in charge: 10 members of the SR team.

Screening method: 10 members above shared the screening of 396 articles. Full screening by checking the full texts determined which articles to choose based on the selection criteria.

Secondary screening result: After the SR team leader's review, 288 out of 396 articles were finally selected for evidence table creation.

Evidence table creation: From the 288 articles selected, 10 members extracted the details from them for a total of 836 pieces of evidence to create an evidence table. (Contents of the evidence table: bibliographic information, study design, PICO, conclusion, and CQs applicable)

(4) Evaluation and consolidation of evidence (creation of CQ summary)

Personnel in charge: SR team leader

Creation of CQ summary: The CQ summary was created by classifying the 836 pieces of evidence extracted by the 10 SR team members by CQ, target disease, and outcome and then summarizing by study design.

Significance of CQ summary creation: The applicable studies focused on rare diseases of allied Hirschsprung's diseases, and the majority of the target articles were case reports and case series. In order to utilize them without disregarding low-evidence-level studies, we adopted a method of carefully extracting evidence based on the CQ and target disease from each article and reorganized the findings as a CQ summary. This method visualized the total pieces of evidence and provided a value, which is different from conventional evidence-level, onto accumulated facts empirically obtained in clinical practice.

(5) Systematic review report

The contents of the CQ summary were recapitulated to make a systematic review report. For every comparison of CQs, the outcomes of benefits and harms were listed, and a consolidated document was created for the judgement of its usefulness.

4. Determination of recommendations regarding the finalization and implementation policy

1) Determination of recommendations

The evidence table, summary by CQ, and systematic review report created by SR team were submitted to the guideline development group, who created proposed recommendations and commentary based on the submitted materials. Since most of the evidence comprised case reports and case series, the strength of the evidence was almost "D", but recommendations were created for the usefulness in clinical practice.
After a consensus meeting, the recommendations were determined by 13 guideline development committee members using the Delphi voting method via e-mail (Table 4). Two committee members in charge of clinical practices for the adult domain declined to vote due to their having limited clinical practice experience in the child domain. Several other committee members also declined to vote for the determination of recommendation on CQ in one’s duty. At the first round of voting, all of the recommendations obtained 90% or greater approval.

2) Finalization
Between December 1 and December 31, 2016, a recommendation draft was posted on the homepages of the Japanese Society of Pediatric Surgeons; the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition; and the Japanese Society of Neurogastroenterology to solicit public comments. It was finalized after an external evaluation by epidemiology specialists (Table 5).

3) Implementation
The detailed version was mailed to major medical institutions and, at the same time, published in research reports. The practical version was issued as a publication and also posted on the homepages of the Japanese Society of Pediatric Surgeons and the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition for dissemination.
Table 2. Database search result 1

<table>
<thead>
<tr>
<th>#</th>
<th>Search formula</th>
<th>Number of literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>#</td>
<td>Search formula</td>
<td>Number of literature</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td></td>
<td>(((CIPO/AL or (chronic/AL and (bowel obstruction·negative/TH or pseudoobstruction/AL))) or (((allied Hirschsprung's disease/AL) or (allied Hirschsprung's disease/AL) or (Immaturity/AL) or (hypoganglionosis/AL) or (neuronal/AL and intestinal/AL and dysplasia/AL) or ((megacystis·microcolon·intestinal hypoperistalsis syndrome/TH or MMIHS/AL)) or (anal achalasia/TH) or (CIIP/AL) or (chronic idiopathic intestinal pseudoobstruction/AL)))) and (PT=except for minutes and CK=human))</td>
<td>477</td>
</tr>
</tbody>
</table>
Table 4. Voting result by guideline development group

<table>
<thead>
<tr>
<th>Number of votes</th>
<th>Number of approvals</th>
<th>Ratio (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CQ1-1</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>CQ1-2</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ1-3</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ2-1</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ2-2</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ2-3</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ3-1</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ3-2</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ3-3</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ4-1</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ4-2</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ4-3</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>CQ5-1</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>CQ5-2</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>CQ5-3</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>CQ6-1</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ6-2</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ6-3</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>CQ7-1</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>CQ7-2</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>CQ7-3</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>
Table 5
Toshio Morizane Chief Visiting Researcher, Japan Council for Quality Health Care

**External evaluation of the Clinical Practice Guideline**

“It is logically summarized and presented with high relevance. This guideline describes the current issues and is considered to be highly useful in areas with poor evidence in clinical practice”.

<table>
<thead>
<tr>
<th>number</th>
<th>Evaluated points</th>
<th>Evaluation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The scope to be handled in the whole medical treatment related to the target disease/health problem is clear (whole or part).</td>
<td>1 2 3 (4)*</td>
<td>A thorough presentation of the medical treatment for Allied Hirschsprung's disease (the diagnosis, medication, surgical therapy, etc.)</td>
</tr>
<tr>
<td>2</td>
<td>The contents conform to the knowledge level of the target guideline users.</td>
<td>1 2 3 (4)</td>
<td>Presentation of professional content that actually corresponds to the medical treatment</td>
</tr>
<tr>
<td>3</td>
<td>The magnitude and certainty of the effect of intervention (diagnosis, treatment, etc.) on the patient’s outcomes are scientifically evaluated based on a systematic review (qualitative/quantitative).</td>
<td>1 2 3 (4)</td>
<td>No CQs can be meta-analyzed. The strength of evidence is evaluated by the quantitative summarization of evidence related to the CQs from articles searched comprehensively.</td>
</tr>
<tr>
<td>4</td>
<td>The benefits and disadvantages (harm, burdens, expenses) of interventions are evaluated in an appropriate manner.</td>
<td>1 2 3 (4)</td>
<td>Whether it is “useful” or &quot;harmful&quot; is evaluated quantitatively.</td>
</tr>
<tr>
<td>5</td>
<td>The strength of the recommendation is based on the importance of multiple outcomes, the magnitude and uncertainty of benefits and harms, and the cost effectiveness. It is also based on a comparison of multiple interventions, if necessary.</td>
<td>1 2 3 (4)</td>
<td>Because the diseases mentioned here are rare, the need for a cost-effectiveness analysis is considered to be low.</td>
</tr>
<tr>
<td>6</td>
<td>The viewpoints of a multi-disciplinary supporting team as well as those of the subjects are reflected in the recommendation.</td>
<td>1 2 (3) 4</td>
<td>The provision of care requiring multi-disciplinary support, such as daily care management and home medical care, should be considered in a future study.</td>
</tr>
<tr>
<td>7</td>
<td>The individual recommendations correspond to the clinical questions, and the subjects, including attributes, are clear.</td>
<td>1 2 3 (4)</td>
<td>Recommendations are presented based on each diagnosis and the patient’s attributes.</td>
</tr>
<tr>
<td>8</td>
<td>The description of individual interventions is concrete and feasible. Facilities, staffs, equipments, etc. are also described, if necessary.</td>
<td>1 2 3 (4)</td>
<td>As the target diseases are rare, it is assumed that care at facilities capable of advanced medical treatment including small intestine transplantation is a prerequisite.</td>
</tr>
<tr>
<td>9</td>
<td>Management is done so that the COI of the guideline creator does not affect the recommendation.</td>
<td>1 2 (3) 4</td>
<td>The creator has no COIs to disclose. Details about the management are unknown.</td>
</tr>
</tbody>
</table>

* Score: 1 Strongly Disagree, 2 Disagree, 3 Agree, 4 Strongly Agree
Figure 16. Literature search flowchart (allied Hirschsprung’s disease)

[4-2. Literature search flowchart] PRISMA statement is modified.
VI. Recommendation

1. CQ1: How are isolated hypoganglionosis, MMIHS, CIIP diagnosed?

<table>
<thead>
<tr>
<th>CQ1-1: How is isolated hypoganglionosis diagnosed?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation: A full-thickness biopsy of gastrointestinal tracts (especially the small intestine and sigmoid colon) is recommended for the definitive diagnosis of isolated hypoganglionosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>(1) (Strong): Recommend “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 (Weak): Suggest “Implementing” or “Not implementing”</td>
</tr>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
</tr>
<tr>
<td></td>
<td>B (Moderate)</td>
</tr>
<tr>
<td></td>
<td>C (Weak)</td>
</tr>
<tr>
<td></td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

Commentary

Isolated hypoganglionosis (HP) is the most difficult disease to diagnose among allied Hirschsprung's diseases. This is because the basic concept of HP is not clear, and a definitive diagnosis method is not clearly established. Reported diagnostic methods for HP include 1) plain abdominal X-ray, 2) gastrointestinal imaging, 3) manometry, 4) a rectal mucosal biopsy, and 5) a gastrointestinal full-thickness biopsy. Among these, many studies have shown that a gastrointestinal full-thickness biopsy (especially from the small and large bowels) was useful for diagnosing HP. This is because the definitive diagnosis of HP has been based on reduced neurocytes in the myenteric plexus (Auerbach's plexus) in many former reports. Some reports have shown that when it is difficult to assess the neurocyte distribution by HE staining, histochemical staining (such as AchE, NADPH, SDH, LDH, silver staining) is useful for the diagnosis.\(^\text{1-30}\) In particular, a questionnaire survey conducted in 2012 for domestic pediatric surgery institutions in Japan reported that an intraoperative frozen section diagnosis had a low accuracy, and a pathological diagnosis by permanent preparation had 94% accuracy.\(^\text{34}\) Therefore, a gastrointestinal full-thickness biopsy has been considered useful in the diagnosis of HP. No complications associated with full-thickness biopsies have been reported.

As for the usefulness of a rectal mucosal biopsy, some reports have recommended a full-thickness biopsy for the final diagnosis of HP, as the former has low accuracy.\(^\text{16, 19, 34}\) The reason is that the submucosal nerve plexus (Meissner's plexus) of HP is normal, and AchE staining is also negative or normal (i.e. it is useful for excluding Hirschsprung's disease, but not useful for the definitive diagnosis of HP).

In addition, plain abdominal radiography and gastrointestinal imaging may not be useful for the definitive diagnosis of HP. Findings obtained from these imaging examination such as the air-fluid level and gas-filled intestine on plain abdominal radiography, and intestinal dilatation, intestinal stenosis, megacolon, microcolon, and caliber change on gastrointestinal imaging are similar to those of other allied Hirschsprung's diseases. A diagnosis therefore cannot be determined by imaging studies alone. Such modalities may also increase unnecessary hazardous X-ray exposure.\(^\text{17, 34-38}\)

The usefulness of manometry conducted for allied Hirschsprung's disease is uncertain. It may
indicate gastrointestinal dysfunction but has low accuracy due to non-constant results in neonatal population, such as reflex negativity, reflex positivity, or atypical reflex. Some articles have reported on esophageal and duodenal manometry, but irregular peristalsis observed in the upper gastrointestinal tracts is not specific to HP. Intestinal manometry is not thought to be useful in the diagnosis of HP.\textsuperscript{18, 21, 23, 24, 34, 37-39}

In conclusion, the most useful examination in the diagnosis of HP is a full-thickness gastrointestinal biopsy, although a rectal mucosal biopsy can be performed first to rule out Hirschsprung's disease. Plain abdominal X-ray, barium enema, and rectal manometry are not useful for the definitive diagnosis of HP and may even cause harm due to X-ray exposure. However, those examinations may be useful for the differential diagnosis of other allied Hirschsprung's diseases.

References


CQ1-2: How is megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) diagnosed?

Recommendation: For cases in which symptoms of bowel obstruction, such as abdominal distension and vomiting, are present during the neonatal period and no organic obstruction is observed, a gastrointestinal series is recommended. When a microcolon is observed and megalocystis is simultaneously confirmed by cystography or computed tomography (CT)/ultrasonography, MMIHS is strongly suspected. An intestinal full-thickness biopsy is recommended for the definitive diagnosis to differentiate it from other allied Hirschsprung's diseases.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong) B (Moderate) C (Weak) D (Very weak)</td>
</tr>
</tbody>
</table>

Commentary

Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) is a serious syndrome with an unknown etiology. Bowel obstructive symptoms are noted from neonatal period, resulting in intestinal failure and accompanied by megalocystis and microcolon.

Diagnostic criteria:

1) Bowel obstruction symptoms such as abdominal distension, vomiting, and abdominal pain present immediately after birth
2) Megacystis present
3) Barium enema reveals microcolon in the neonatal period
4) No mechanical obstructive lesion observed in the gastrointestinal tract
5) No pathological abnormality observed in the neural plexus in specimen with a full-thickness intestinal biopsy

All five of these items need to be met.

Although plain abdominal X-ray is indispensable for the diagnosis of bowel obstruction, an extended gas pattern of the stomach and small bowel are general findings for bowel obstruction in neonates, so the diagnosis can rarely be determined based on X-ray findings alone. However, the observation of a lower abdominal mass shadow due to megalocystis on abdominal X-ray may be useful for the diagnosis.1, 2

Enema is useful for the confirmation of microcolon, an indispensable sign of this disease. Note that ileal atresia and Hirschsprung's disease (entire colon aganglionosis) also present with both gastrointestinal obstructive symptoms and microcolon during the neonatal period, so these diseases may be difficult to differentiate by contrast enema.

If megalocystis is indicated with the symptoms of gastrointestinal obstruction, MMIHS should be considered. Although cystography can be useful for a clear diagnosis of megalocystis, no further clinical information can be obtained using this modality. Ultrasonography or computed tomography (CT) can be alternative diagnostic imaging methods for the diagnosis of megalocystis.

Due to severe abdominal distension, laparotomy is performed during the neonatal period in many cases. MMIHS is often diagnosed based on the intra-operative findings. A full-thickness intestinal biopsy
is indispensable during laparotomy, as other allied Hirschsprung’s diseases, such as CIIP and isolated hypoganglionosis, must be differentiated. In addition, extensive Hirschsprung’s disease and hypoganglionosis, can be differentiated with a full-thickness biopsy. MMIHS is characterized by the absence of abnormalities in ganglion cells.\(^3\)\(^4\) MMIHS must also be differentiated from CIIP, as neither of them have abnormalities in ganglion cells; the former can be distinguished by the presence of megalocystis and microcolon during the neonatal period. If possible, the ganglion cells should be checked using frozen sections and the histology should be confirmed using permanent preparations. No hypertrophic AcE-positive nerve fibers are seen in the rectal mucosa with a suction biopsy, so Hirschsprung’s disease can be differentiated, but it is difficult to differentiate MMIHS from other allied Hirschsprung’s diseases using a suction biopsy.

Prenatal diagnoses have often been made in recent years based on a dilated intestinal tract and megalocystis.\(^5\)\(^6\)\(^7\) Progressive cystectasy, hydroureronephrosis, and gastrointestinal dilatation are characteristic findings in the prenatal period.

**References**


CQ1-3: How is chronic idiopathic intestinal pseudo-obstruction (CIIP) diagnosed?

Recommendation: The duration of symptoms and the bowel obstruction conditions are determined from the clinical history and physical examination findings. The presence of intestinal dilatation, air-fluid level formation, and the absence of mechanical obstruction are confirmed by diagnostic imagings. For children, an intestinal full-thickness biopsy is recommended for the definitive diagnosis to differentiate it from other allied Hirschsprung's diseases. For adults, it is important to differentiate true mechanical obstruction and secondary intestinal pseudo-obstruction, and a full-thickness biopsy is not conducted as it is for children.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
</tr>
<tr>
<td></td>
<td>B (Moderate)</td>
</tr>
<tr>
<td></td>
<td>C (Weak)</td>
</tr>
<tr>
<td></td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

Commentary

The diagnosis of CIIP requires all of the following 4 items to be met.

1) Chronic bowel obstruction observed
2) Intestinal dilatation and air-fluid levels on diagnostic imaging
3) No intramural obstruction of the gastrointestinal tract
4) Other diseases excluded

A duration of symptoms ≥2 months for children and ≥6 months for adults shall be confirmed.

Intestinal dilatation and air-fluid levels are diagnosed by plain abdominal X-ray, CT, MRI, or similar modalities. For neonates, radiological examinations in a standing or lateral decubitus position may be difficult, so the confirmation of air-fluid levels by plain abdominal X-ray is not necessarily required.

In the diagnosis of pediatric intestinal pseudo-obstruction, the location of dilated segments, the degree of peristaltic disorder, and the presence of non-mechanical obstruction can be detected based on the gastrointestinal gas pattern on plain abdominal X-ray and gastrointestinal series. For adults, luminal obstructions caused by neoplastic lesions, inflammation, and adhesion need to be excluded.

The diagnosis of idiopathy requires the exclusion of other pseudo-obstructions.

For children, diseases classified as primary pseudo-obstructions need to be differentiated. Although congenital aganglionosis (Hirschsprung's disease) can be diagnosed by a suction rectal mucosal biopsy, a pathological evaluation by a full-thickness bowel biopsy is indispensable for the differential diagnosis of isolated hypoganglionosis and immaturity of ganglia.

In adults, primary intestinal pseudo-obstructions other than CIIP are rare, and the exclusion of secondary pseudo-obstructions is emphasized in the diagnosis of idiopathy. The secondary pseudo-obstructions to be differentiated are listed in Table 1.

Cine MRI and intestinal manometry are useful for assessing peristaltic disorders present in CIIP, and these two examinations are used instead of a full-thickness biopsy in adults.
References


2. CQ2: What kind of drug therapy is recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?

CQ2-1: What kind of drug therapy is recommended for the treatment of isolated hypoganglionosis?

Recommendation: No drug therapy for isolated hypoganglionosis is recommended at this point.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

Drug therapies for isolated hypoganglionosis are performed in various institutions and include prokinetic agent, probiotics, Chinese medicine (Dai-kenchu-to), antibiotics, enemas, laxatives, and antidiarrheal drugs. However, no randomized controlled trial (RCT) or case series has described the efficacy of these treatments. There is only one case report on probiotics\(^1\), and one case report mentioning the use of anticholinergic or prostaglandin preparation.\(^2\)

As mentioned, the efficacy of the Chinese medicine (Dai-kenchu-to), which is often used clinically in Japan, is still unknown. Regarding probiotics, a case report\(^1\) showed that the administration of probiotics increased the amount of enteral nutrition and decreased the frequency of enteritis, but no other reports have been found to support its results. Anticholinergic or prostaglandin preparation drugs may have no effect on improving the gastrointestinal motility in case of isolated hypoganglionosis\(^2\), as only one report exists and the effectiveness is unclear. Note that no adverse events have been reported to be associated with any of the drugs mentioned above.

At present, based on the available evidence, no drug can be recommended as an effective agent, that improves gastrointestinal functional disorder or symptoms accompanying isolated hypoganglionosis.

**References**


CQ2-2: What kind of drug therapy is recommended for megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?

**Recommendation:** Although the usefulness of Chinese medicines (Dai·kenchu·to) or probiotics has been reported as drug therapy for MMIHS, evidence is insufficient to recommend these therapies at present.

**Evidence**

<table>
<thead>
<tr>
<th></th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

Prokinetic agents (e.g. cisapride, metoclopramide), probiotics, Chinese medicine (Dai·kenchu·to), antibiotics (e.g. erythromycin), enemas, laxatives, and antidiarrheal drugs are sometimes used to treat MMIHS. Some case reports have described their efficacies, but there are no RCTs or case series to support these findings. Prokinetic agents, such as cisapride (no longer marketed in Japan) and metoclopramide are sometimes used, and their effectiveness was investigated in six case reports.\(^1\text{–}^6\) All of the reports concluded that these agents are ineffective in improving gastrointestinal motility. For replacement of cisapride, mosapride, a serotonin receptor agonist is now available in the Japanese market. However, no reports have yet focused on the effect.

The Chinese medicine (Dai·kenchu·to) has been reported to be effective in four case reports.\(^7\text{–}^{10}\) This agent reportedly induces improvement in the gastrointestinal motility and intestinal transit time,\(^7\) an increased amount of enteral nutrition intake,\(^8\) and improvement in bowel obstruction symptoms.\(^9\text{,}^{10}\) The effects of probiotics have been described in only one case report,\(^11\) in which probiotics were administered via lower jejunostomy to prevent enteritis, and enteritis did not develop. The effects of antibiotics have been described three case reports,\(^5\text{,}^6\text{,}^{10}\) in which the effectiveness of erythromycin was investigated, but the results did not show any effectiveness.

Some case reports have described the administration of pantothenic acid, prostaglandin, or a sympathetic blocker, none of which had any effect to improve the gastrointestinal motility.

In conclusion, no drug therapy can be recommended, but the Chinese medicine Dai·kenchu·tou and probiotics may be attempted, as their effectiveness has been described in some case reports. Note that no adverse events have been reported to be associated with any of the drugs mentioned above.

**References**


CQ2-3: What kind of drug therapy is recommended for the treatment of chronic idiopathic intestinal pseudo-obstruction (CIIP)?

**Recommendation:** As drug therapies for CIIP, prucalopride, cisapride, Chinese medicines (Dai-kenchu-to), probiotics, and antibiotic (erythromycin) are sometimes used, and some reports have shown the usefulness of those agents for functional gastrointestinal disorder or abdominal symptoms. However, evidence is insufficient to recommend these therapies at present.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

Some drugs are used to control CIIP, including prokinetic agents (e.g. prucalopride, cisapride), a Chinese medicine (Dai-kenchu-tou), probiotics, antibiotics (e.g. erythromycin, polymyxin B), enema, laxatives, and antidiarrheals. However, there are few RCTs or case series to support the evidence, and most of the available articles are case reports.

The efficacy of prokinetic agents, such as prucalopride and cisapride (no longer marketed in Japan), have been reported. Prucalopride is a 5-HT4 receptor agonist and unapproved in Japan. One case series report\(^1\) investigated the effectiveness of prucalopride in seven cases in their protocol, and three of four who completed the protocol showed improvement of obstructive symptoms. It should be noted that three patients withdrew from this protocol, but none of them had adverse events. In addition, one cross-sectional study\(^2\) has reported improvement in bowel obstructive symptoms with cisapride. Furthermore, six case reports showed the usefulness of cisapride, including an increased amount of enteral nutrients\(^3,4\), reduction in the intestinal transit time\(^5\), and improvement in bowel obstructive symptoms.\(^6-8\) However, conversely, three case reports\(^9-11\) reported that cisapride was ineffective. The efficacy seems to vary depending on the pathology of individual cases. The effectiveness of mosapride, a serotonin receptor agonist now marketed in Japan to replace cisapride, for CIIP has not yet been reported.

Two case reports\(^12,13\) described the usefulness of the Chinese medicine Dai-kenchu-tou in improving gastrointestinal motility and bowel obstructive symptoms. However, one case report\(^14\) found it to be ineffective. The evidence supporting the usefulness is thought to be scarce. Note that no adverse events have been reported to be associated with Dai-kenchu-tou.

Two case reports\(^15,16\) have described the efficacy of probiotics. In these reports, an increased intake of enteral nutrition and reduced incidence of enteritis were reported. Although there have been reports describing their ineffectiveness, the evidence supporting their effectiveness is not sufficient. Note that no adverse events have been reported to be associated with probiotics.

Regarding antibiotics, four case reports\(^14,17-19\) showed the effectiveness of erythromycin. Erythromycin was administered with the expectation of enhancing intestinal motility, and most of these reports described increased enteral nutrition intake and improvement in bowel obstructive symptoms. There have been no reports of ineffectiveness, nor any adverse events. Metronidazole and polymyxin B
are administered to control the intestinal flora. Of the two drugs, only polymyxin B has been reported with regard to its efficacy against CIIP. However, findings have been conflicting; one case report described the improvement of symptoms, and two case reports indicated ineffectiveness. No adverse events were reported. Erythromycin may be effective, but the evidence is poor, and the efficacy of polymyxin B is considered unclear.

Regarding other drugs, one case report found laxatives to be effective. Improvement in bowel obstructive symptoms by a cholinergic agent was shown in a case report, but this effect was denied in four other case reports. The effectiveness of laxatoves is therefore still unknown. Prostaglandin has also been used, and two case reports found that they improved bowel obstructive symptoms, but three reports showed ineffectiveness. The effect of this drug in improving symptoms is also unknown. Buprenorphine, a weak opioid, was reported as an agent for relieving abdominal pain. Although evidence is not sufficient, it may be useful for relieving symptoms of abdominal pain associated with CIIP as well.

In conclusion, there are no recommended medications, but probiotics and erythromycin may be attempted, as their effectiveness has been shown in some case reports.

References


3. CQ3: Is gastrointestinal decompression therapy recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?

| CQ3-1: Is gastrointestinal decompression therapy recommended for the treatment of isolated hypoganglionosis? |
| Recommendation: Upper jejunostomy is suggested for isolated hypoganglionosis. Ileostomy may be effective for some cases, but the effectiveness of enterostomies at any other part of the intestinal tract is unknown. |
| Strength of recommendation | 1 (Strong): Recommend “Implementing” or “Not implementing” |
| Evidence | A (Strong) |
| | B (Moderate) |
| | C (Weak) |
| | D (Very weak) |

**Commentary**

Isolated hypoganglionosis is a disease that requires prolonged fasting and central venous nutrition management due to enteritis caused by stagnation of intestinal contents, subsequent sepsis, and abdominal pain. Effective gastrointestinal decompression may enable enteral feeding and provide the expectation of growth and a long-term survival. Enterostomy sites have been discussed in case series and case reports.

Regarding the type of gastrointestinal decompression, only one case has described gastrostomy with concomitant decompression via high jejunostomy: this approach enabled enteral nutrition\(^1\), and intestinal lavage was empirically performed in the reported case at the time of exacerbation. The prognosis varies depending on the location of the enterostomy, and effective usage of the enterostomy may enable enteral feeding in many cases. Compared with ordinal jejunostomy and ileostomy, high jejunostomy is significantly more effective with regard to X-ray images, the survival rate\(^2\), and the incidence of bowel obstruction\(^3\), with good outcomes.\(^4, 5\) The effectiveness of ileostomy is unclear. There have been cases requiring ileectomy due to functional failure\(^6\), and enterostomy was re-performed at a higher position\(^3\). However, there was also a case of improved bowel obstruction\(^4\). There are no reports of effective colonostomy, and additional enterostomy was required in the reported cases.\(^3, 7\)

**References**


CQ3−2: Is gastrointestinal decompression therapy recommended for the treatment of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?

Recommendation: No evidence supports the positive recommendation of gastrointestinal decompression for MMIHS.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

MMIHS is a serious disease that requires prolonged fasting and central venous nutrition management due to enteritis caused by peristaltic disorder, subsequent sepsis, and abdominal pain.

Regarding gastrointestinal decompression therapy for MMIHS, some reports have shown that tube decompression did not improve the symptoms\(^1\), and enteral feeding was not enabled by decompression via gastrostomy, even with simultaneous enterostomy\(^2\), despite being effective for isolated hypoganglionosis. Regarding intestinal lavage, there was a case\(^3\) in which switching to antegrade lavage by Malone surgery after transanal lavage resulted in being able to provide home care to the patient. Regardless of the enterostomy site, enterostomy can only temporarily\(^4\) or partially\(^5\) relieve symptoms and does not contribute to prognostic improvement.\(^6\) Colonostomy is ineffective.\(^7\) No side effects or adverse events accompanying decompression therapy have been reported.

**References**


**CQ3-3: Is gastrointestinal decompression effective for chronic idiopathic intestinal pseudo-obstruction (CIIP)?**

**Recommendation:** Intermittent decompression via enteric tube may be effective in some CIIP cases, and enterostomy may be effective in other cases. The appropriate approach should be considered on a case-by-case basis.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
<th>(2) (Weak): Suggest “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
<td>B (Moderate)</td>
</tr>
<tr>
<td></td>
<td>C (Weak)</td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

**Commentary**

CIIP is a disease that requires repeated, prolonged fasting and central venous nutrition management due to enteritis caused by stagnation of intestinal contents, subsequent sepsis, and abdominal pain. Effective gastrointestinal decompression may enable enteral feeding and provide the expectation of growth and long-term survival. However, which type of gastrointestinal decompression therapy is most effective depends on each case.

Tube decompression as a gastrointestinal decompression therapy for CIIP reported to be effective in some cases and ineffective in others. One case reported that the bowel obstruction symptoms were remitted with nasogastric tube and enteral nutrition was enabled, but the bowel obstruction symptoms relapsed. For ileus tube, there was a case of marked improvement in abdominal distension and abdominal pain; however, there have been some cases of ineffectiveness and no improvement in intestinal dilatation. There have been cases in which the oral intake was enabled by intestinal lavage and continuous decompression through enterostomy, in which high jejunostomy temporarily improved bowel obstruction symptoms and enabled a small amount of oral intake, and in which ileostomy was effective. Nevertheless, the ineffectiveness of enterostomy has also been reported. Colonostomy has not been shown to be effective in any cases and has been reported not to have improved bowel obstruction symptoms even with simultaneous ileostomy. No side effects or adverse events accompanying decompression therapy have been reported.

**References**

1395-401. (Article in Japanese)
4. CQ4: Is nutrition therapy recommended for isolated hypoganglionosis, MMIHS, and CIIP?

CQ4-1: Are enteral nutrition and parenteral nutrition effective as nutritional therapies for isolated hypoganglionosis?

Recommendation: Enteral nutrition and parenteral nutrition are recommended as nutritional therapies for isolated hypoganglionosis.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
<th>2 (Weak): Suggest “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
<td>B (Moderate)</td>
</tr>
</tbody>
</table>

Commentary

Aside from a few case reports, few papers have discussed nutritional therapy for isolated hypoganglionosis. The evidence level is very low. However, for this disease, which can develop during the neonatal period, parenteral nutrition therapy is clinically performed from an early stage in most of the cases, and enteral feeding therapy is combined with it once the disease condition is stabilized after stoma construction. Recommending parenteral nutrition and enteral nutrition as nutritional treatments is considered to be appropriate.

For parenteral nutrition, there are reports in which intermittent central venous nutrition was useful for preventing hepatic dysfunction\(^1\) and in which home total parenteral nutrition using an implanted central vascular catheter was useful.\(^2\) As central venous nutrition may be an indispensable and long-term nutrition treatment for this disease, its complications need to be well recognized for its safe implementation. Furthermore, since it is a long-term therapy, a catheter with a cuff or an implanted central vascular catheter needs to be used for infection prevention, and home total parenteral nutrition should also be taken into consideration.

Enteral nutrition has never been specifically reported in papers, and the clinical managements depend on the efforts and ideas of each institution. Because a small intestinal stoma is constructed in many cases at present, some kind of enteral nutrition may be indispensable. Although breast milk, adjusted milk, semidigested nutrient, digestive nutrient, and elemental diet have all been appropriately used as enteral nutrients, the most appropriate nutrient has not yet been determined.

Nutritional therapy should be considered in combination with surgical treatment and medications for this disease.

References

CQ4-2: Are enteral nutrition and parenteral nutrition useful as nutritional therapies for megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?

**Recommendation:** Enteral nutrition and parenteral nutrition are recommended as nutritional therapies for MMIHS.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>① (Strong): Recommend “Implementing” or “Not implementing”</th>
<th>② (Weak): Suggest “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
<td>B (Moderate)</td>
</tr>
<tr>
<td></td>
<td>C (Weak)</td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

**Commentary**

This disease is still a disease with a poor prognosis, and peristalsis dysfunction with unknown etiology develops during the neonatal period. A nationwide survey in Japan showed that total parenteral nutrition (TPN) was needed for 4 cases and a combination of parenteral and enteral nutrition was needed for 12 cases out of 19 definitively diagnosed cases. In 7 out of the 9 surviving cases at present, parenteral nutrition has been required. Based on these survey results and the fact that saving the lives of children with MMIHS is clinically difficult without enteral and parenteral nutrition support, parenteral and enteral nutrition are deemed appropriate for this disease, although the evidence level is low.

Three articles support the usefulness of parenteral nutrition: one reported on the promotion of growth hormone secretion with nocturnal cyclic TPN\(^1\), another showed its usefulness over a short period of time\(^2\), and another reported on the long-term survival on cyclic TPN.\(^3\) However, there have been reports of associated adverse events, including repeated catheter-related bloodstream infection caused by long-term central venous nutrition\(^4\)\(^-\)\(^7\), cholestatic hepatic dysfunction\(^6\)\(^,\)\(^8\)\(^-\)\(^10\), the development of portal hypertension symptoms\(^11\), and copper deficiency.\(^12\) When providing parenteral nutrition, clinicians should be familiar with the risk of those adverse events and perform appropriate preventative measures and treatments.

The usefulness of enteral nutrition has been reported.\(^13\) The effectiveness of combination with parenteral nutrition has also been reported.\(^14,\)\(^15\) However, these findings have been cited in a limited number of case reports and the evidence level is low. Regarding enteral nutrition for this disease, effective methods and appropriate nutrients need to be determined in the future.

**References**


CQ4·3: Are enteral nutrition and parenteral nutrition effective as nutritional therapies for chronic idiopathic intestinal pseudo-obstruction (CIIP)?

Recommendation: Enteral nutrition and parenteral nutrition are recommended as nutritional therapies for CIIP.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend &quot;Implementing&quot; or &quot;Not implementing&quot;</th>
<th>2 (Weak): Suggest &quot;Implementing&quot; or &quot;Not implementing&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
<td>B (Moderate)</td>
</tr>
<tr>
<td></td>
<td>C (Weak)</td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

Commentary

This disease may develop in neonates or older children. In both cases, intestinal peristaltic disorder may persist over a long period of time, and some kind of nutritional therapy is indispensable. Thus, the recommendation of nutritional therapy for this disease is deemed appropriate. While the evidence level may be weak, as most of the evidence supporting the application of nutritional therapy for this disease is from case reports, like for isolated hypoganglionosis and MMIHS the number of reports is slightly higher, and some reviews have been written.

Nine articles have described the usefulness of parenteral nutrition. The usefulness reported includes the effect of fatty acid emulsion on hepatic steatosis, improvement of bowel obstruction symptoms, and improvement in the quality of life by cyclic TPN using an implanted central vascular catheter. However, there are some case reports and reviews regarding adverse events, such as trace element deficiency, electrolyte disturbance, and sudden death due to trace element deficiency on long-term central venous nutrition. Since this disease may have a long duration of symptoms, special attention needs to be paid to the complications related to long-term parenteral nutrition.

The efficacy of enteral nutrition was reported in seven case reports and one review. Its usefulness has been reported with respect to the use of semidigested nutrients, concomitant use of semidigested nutrients and a low-residue diet, use of semidigested nutrients and/or digestive nutrients, and a reduction in the frequency of ileus symptoms with semidigested nutrients. Furthermore, two articles describe the usefulness of concomitant parenteral and enteral nutrition. However, a lack of any marked contribution of enteral nutrition to the improvement in bowel obstruction symptoms has also been reported. Although some trends support the efficacy of semi-digested nutrients or digestive nutrients, they may not be able to be administered in cases with aggravated symptoms. Further investigation into what kinds of enteral nutrients are most useful is needed.

References


CQ5: Is radical surgical treatment recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?

<table>
<thead>
<tr>
<th>CQ5·1: Is radical surgical treatment (other than stoma construction) recommended for the treatment of isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation: Avoiding radical surgical treatment is suggested.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>① (Strong): Recommend “Implementing” or “Not implementing”</td>
<td>A (Strong)</td>
</tr>
<tr>
<td>② (Weak): Suggest “Implementing” or “Not implementing”</td>
<td>B (Moderate)</td>
</tr>
<tr>
<td>(Weak)</td>
<td>C (Weak)</td>
</tr>
<tr>
<td>(Very weak)</td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

Commentary

Isolated hypoganglionosis is an allied Hirschsprung's disease that causes intestinal motility disorder despite the presence of ganglion cells in the bowel wall. The ganglion cells are congenitally small in size, and an extreme reduction in the number of ganglia plexi and ganglion cells is observed. Although there is a difference in the degree, a reduction in the number of ganglion cells is observed all across the intestinal tract. Nutrition support using central venous nutrition and enteral nutrition, and enterostomy at an appropriate site for decompression in order to prevent congestive enteritis are required in the treatment.\(^1\) The effectiveness of intestinal resection at the anal side of enterostomy has also been showed in some case reports. A systematic review showed that intestinal resection and tapering improved bowel obstruction symptoms.\(^2\) However, as peristaltic disorder is observed all over the intestinal tract, radical surgery is not yet established.

References


CQ5·2: Is radical surgical treatment (other than stoma construction) recommended for the treatment of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?

Recommendation: Resection of dilated intestines does not improve ileus symptoms in MMIHS, so avoiding radical surgical treatment is suggested.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (Strong)</td>
<td>Recommend “Implementing” or “Not implementing”</td>
</tr>
<tr>
<td>2 (Weak)</td>
<td>Suggest “Implementing” or “Not implementing”</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

Four case reports had useful findings for this CQ. No symptom improvement has been reported. Both Martin type jejunum side-to-side anastomosis, and additional small intestinal resection and right hemicolecotmy were reported not to improve the symptoms.1) Resection of the dilated segment did not improve the symptoms of abdominal distension or ileus, nor was the effectiveness of radical surgery confirmed in the literature.2)

**References**


CQ5-3: Is radical surgical treatment (other than stoma construction) recommended for the treatment of chronic idiopathic intestinal pseudo-obstruction (CIIP)?

Recommendation: Concomitant use of antegrade continence enema and antidromic enema is suggested for the treatment of CIIP to improve defecation. In cases with duodenal dilatation, duodenojejunostomy is suggested to improve the intestinal transit. It may relieve the pseudo-obstructive symptoms to some extent. Intestinal resection does not improve the pseudo-obstructive symptoms, so avoiding radical surgical treatment is suggested.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (Strong)</td>
<td>Recommend “Implementing” or “Not implementing”</td>
</tr>
<tr>
<td>2 (Weak)</td>
<td>Suggest “Implementing” or “Not implementing”</td>
</tr>
</tbody>
</table>

Evidence

<table>
<thead>
<tr>
<th>1 (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (Strong)</td>
<td>B (Moderate)</td>
<td>C (Weak)</td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

**Commentary**

Six case reports had useful findings for this CQ.

**Beneficial outcomes:**

Antegrade continence enema improved defecation remarkably, but improved abdominal distension mildly. Duodenojejunostomy, in the case of duodenal dilatation, improved the transit of the dilated intestine remarkably, and improved the symptoms to some extent. Ileocecal resection reduced the transit time of contrast medium to reach the colon in imaging examinations.

**Harmful outcomes:**

Ileocecal resection and colectomy did not improve bowel obstruction symptoms. Based on the report of surgery-related death, attempting radical surgery for chronic intestinal pseudo-obstruction could be harmful.

**References**


CQ6: Is small bowel transplantation recommended for the treatment of isolated hypoganglionosis, MMIHS, and CIIP?

<table>
<thead>
<tr>
<th>CQ6-1: Is small bowel transplantation useful for the treatment of isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation:</strong> Small bowel transplantation is suggested for the treatment of isolated hypoganglionosis, as it may be useful for the following cases: patients in whom discontinuing parenteral nutrition (PN) is difficult even after the maximum use of the native intestinal tract under intestinal rehabilitation; patients in whom the number of central venous access routes is lacking; patients with repeated episodes of sepsis; and patients with progressive hepatopathy.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 (Weak): Suggest “Implementing” or “Not implementing”</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

According to the Intestinal Transplant Registry, small bowel transplantation was performed in 2,600 cases or more by 2011 all over the world. Among them, patients with motility disorder as primary disease accounted for 15% of adults and 19% of children. In Japan, the first small bowel transplantation was performed in 1996, and 26 transplantations in 23 cases were performed by 2014. The postoperative patient survival and graft survival rates at 1, 5, and 10 years are 87%, 68%, 58%; and 80%, 59%, 44%, respectively. The short-term results are relatively good, but the long-term prognosis is still poor.¹)

Articles from overseas regarding small bowel transplantation for isolated hypoganglionosis cannot be found, probably because there are no common worldwide diagnostic criteria. Only one case from Tohoku University has been addressed in papers.²,³) A 14-year-old boy who had a history of 10 laparotomies was experiencing progressive difficulty with oral intake due to multiple stenoses of the small bowel secondary to repeated enteritis and abdominal pain, and a progressive lack of central venous access routes. The patient reportedly achieved successful oral intake after the transplantation, which led to discontinuing parenteral nutrition and being discharged.⁴,⁵)

The following five institutions have performed small bowel transplantation: Kyoto University, Osaka University, Tohoku University, Keio University, and Kyushu University. An overview of small bowel transplantation cases for hypoganglionosis in Japan as of January 2016 based on a report from the Japanese Intestinal Transplantation Registry and confirmation with the transplantation institutions is shown in Table 6. Nine small bowel transplantations (living donors: 6, brain-dead donors: 3) in 8 cases have been performed so far: the patient survival was 7/8 (88%), and the graft survival was 5/9 (56%). Among the 5 cases of graft survival, complete discontinuation without requiring any transfusion at all was achieved in 3/5 (60%) cases, and 2/5 (40%) cases temporarily or always required transfusion. Stoma closure was performed in 1/5 (20%) cases; partial closure, such as Bishop-Koop and Santulli, was performed in 2/5 (40%) cases; and 2/5 (40%) cases remained open.

Small bowel transplantation for isolated hypoganglionosis has been performed in cases where disease management is difficult due to a lack of central venous access or repeated episodes of sepsis. While there are patients who benefitted from transplantation, such as achieving successful oral intake and a reduced dependency on parenteral nutrition, acute rejection and chronic rejection may result in graft removal in
many cases. Given that the graft survival rate has remained at 56%, we should carefully determine the indications of small bowel transplantation as a surgical treatment for isolated hypoganglionosis, and establishing control with the patient’s own intestine should be given the highest priority.

References

Table 6. Cases of small bowel transplantation for isolated hypoganglionosis in Japan

<table>
<thead>
<tr>
<th>Case</th>
<th>Year of transplant</th>
<th>Institution</th>
<th>Age</th>
<th>Sex</th>
<th>Indication for transplantation</th>
<th>Living/Brain-dead</th>
<th>Patient survival</th>
<th>Graft survival</th>
<th>PN</th>
<th>Stoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2003</td>
<td>Tohoku University</td>
<td>14</td>
<td>Male</td>
<td>Repeated sepsis</td>
<td>Living</td>
<td>Survival</td>
<td>Survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2006</td>
<td>Keio University</td>
<td>14</td>
<td>Male</td>
<td>PN dependence, Lack of central venous access</td>
<td>Living</td>
<td>Survival</td>
<td>Survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2007</td>
<td>Keio University</td>
<td>11</td>
<td>Male</td>
<td>PN dependence, Lack of central venous access</td>
<td>Living</td>
<td>Survival</td>
<td>Survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2007</td>
<td>Tohoku University</td>
<td>28</td>
<td>Female</td>
<td>Repeated sepsis, Lack of central venous access</td>
<td>Living</td>
<td>Survival</td>
<td>Resection (ACR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4'</td>
<td>2007</td>
<td>Tohoku University</td>
<td>27</td>
<td>Female</td>
<td>Graft failure due to ACR</td>
<td>Brain-dead</td>
<td>Survival</td>
<td>Resection (CR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2011</td>
<td>Keio University</td>
<td>13</td>
<td>Male</td>
<td>PN dependence, Lack of central venous access</td>
<td>Living</td>
<td>Survival</td>
<td>Resection (CR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2011</td>
<td>Kyoto University</td>
<td>10</td>
<td>Female</td>
<td>Hepatopathy, Nutritional deficiency, CRBSI</td>
<td>Brain-dead</td>
<td>Death</td>
<td>Patient death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>2013</td>
<td>Tohoku University</td>
<td>20</td>
<td>Male</td>
<td>Brain-dead</td>
<td>Brain-dead</td>
<td>Survival</td>
<td>Survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>2014</td>
<td>Keio University</td>
<td>10</td>
<td>Male</td>
<td>Repeated sepsis, Lack of central venous access</td>
<td>Living</td>
<td>Survival</td>
<td>Survival</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Case 4’ is the re-transplantation case of case 4.
CQ6-2: Is small bowel transplantation useful for megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?

**Recommendation:** Small bowel transplantation is suggested for cases not complicated with liver or renal failure. Multiple organ transplantation is suggested for cases complicated with liver or renal failure.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>strength of recommendation</td>
<td>2 (Weak): Suggest “Implementing” or “Not implementing”</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

MMIHS is the most serious type of diseases presenting with functional ileus. In many cases, the symptoms develop from an early stage after birth with a poor prognosis.\(^1\) The associated causes of death include sepsis, malnutrition, hepatic failure, renal failure, and multiple organ failure, and no specific method of treatment has been established.\(^2\)\(^,\)\(^3\)

Small bowel transplantation for MMIHS has never been performed in Japan (as of January 2016). Papers on organ transplantation have been reported only from overseas, and most of the cases reported are multiple organ transplantations including the stomach, small bowel, colon, liver, pancreas, and kidney, as hepatic failure and renal failure are accompanied at the time of transplantation in the majority of reported cases.\(^1\)\(^,\)\(^2\)\(^,\)\(^4\)\(^-\)\(^6\) There is one case report of an eight-year-old girl without hepatic or renal failure at the time of transplantation, and isolated small bowel transplant helped her to achieve oral intake.\(^7\)

Another case describes a one-year-old girl who successfully received combined living donor liver/small bowel transplantation from her mother.\(^8\) In multiple organ transplantation, there are many cases in which the stomach is simultaneously transplanted to prevent postoperative gastric motility disorder. However, in cases of isolated small bowel transplantation and combined living donor liver/small bowel transplantation, the postoperative gastric emptying function was improved in both cases, and it has been suggested that the stomach does not necessarily need to be transplanted simultaneously.

The patient and graft survival rates after small bowel transplantation are poor in the long term. However, considering the otherwise extremely poor prognosis of MMIHS, multiple organ transplantation historically only being performed overseas, and the difficulties of combined liver/small bowel transplantation in Japan, isolated small bowel transplantation might be useful when the disease is not complicated with hepatic failure. This is the current situation of small bowel transplantation for MMIHS in Japan.

**References**


CQ6-3: Is small bowel transplantation useful for chronic idiopathic intestinal pseudo-obstruction (CIIP)?

**Recommendation:** Small bowel transplantation for the treatment of CIIP is suggested, as it may be useful for the following cases: patients whose symptoms remain intolerable even with adequate parenteral nutrition, enteral nutrition, and gastrointestinal decompression therapy; patients in whom the number of central venous access routes is lacking; and patients with repeated episodes of sepsis. The impaired native gastric outlet function needs to be considered when small bowel transplantation is planned and performed.

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>1 (Strong): Recommend “Implementing” or “Not implementing”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence</td>
<td>A (Strong)</td>
</tr>
<tr>
<td></td>
<td>B (Moderate)</td>
</tr>
<tr>
<td></td>
<td>C (Weak)</td>
</tr>
<tr>
<td></td>
<td>D (Very weak)</td>
</tr>
</tbody>
</table>

**Commentary**

CIIP is a functional bowel obstruction with an unknown etiology. Treatment may start with conservative treatments, such as drug therapy and intravenous and enteral nutrition, and then shift to invasive treatments, such as decompression by tubing or enterostomy, as the condition progresses. In the cases in which intolerable pain is present despite these treatments, and in which the disease is complicated by a lack of central venous access or repeated episodes of sepsis, small bowel transplantation may be performed as a final measure.

Since this disease is often characterized by disorder of gastric emptying, multiple organ transplantation including the stomach has been generally performed overseas. A group from the University of Bologna in Italy performed transplantation in 11 cases with CIPO accompanied by functional disorder of gastric emptying. Multiple organ transplantation was performed only for two cases, and for the remaining nine cases, isolated small bowel transplantation and partial gastrectomy with graft-gastric and graft-duodenal anastomoses were performed. In 6 (86%) out of the 7 surviving cases, oral intake was enabled, and in 5 cases (71%), gastric emptying was normalized.

In Japan, small bowel transplantation for CIIP has been performed in three cases. In two of these cases, two anastomoses were performed at the oral side to add graft-duodenal or graft-jejunal anastomosis to graft-gastric anastomosis. In both cases, however, oral intake was not easily established. Only one out of the three cases has survived.

CIIP is an intractable disease with an unknown etiology for which an effective treatment method has not yet been established. Small bowel transplantation may be the only therapy for severe cases, but the oral intake is not easily established after transplantation. As for the current situation regarding small bowel transplantation for CIIP in Japan, multiple organ transplantation is not feasible. Isolated small bowel transplantation should be provided carefully with close consideration of the appropriate anastomosis approach for ensuring the gastric emptying function in each case.

**References**


7. CQ7: What is the prognosis of isolated hypoganglionosis, MMIHS, and CIIP?

<table>
<thead>
<tr>
<th>CQ7-1: What is the prognosis of isolated hypoganglionosis?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation: A long-term survival can be expected with appropriate treatment. In many cases, adequate nutritional support and intestinal stoma care are required for a long period of time.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

In article of a systematic review\(^1\), multidisciplinary treatment improved the survival rate from 12.6% in 1977 to 55.6% in 2011. When patients receive appropriate therapy, a longer survival can be expected. Of these cases, there are some in which disease control was obtained with oral intake alone, in which normal growth or only mild growth disorder was observed, and in which school attendance was achieved. However, many cases may require long-term management of nutrition and enterostomy.

**References**

CQ7·2: What is the prognosis of megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)?

Recommendation: Patients with MMIHS have a poor prognosis compared to healthy children; however, a long-term survival can be expected with appropriate treatment. In many cases, adequate nutritional support and intestinal stoma care are required, and the functional prognosis is poorer than that of healthy children.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

A cross-sectional study in Japan showed that 10 out of 19 cases were surviving and 9 cases were dead, with a 5-year survival rate of 62.8% and 10-year rate of 56.5%. The main causes of death were hepatic failure and sepsis. In 2 systematic reviews, the number of surviving cases was 43 out of 218 cases\(^1\) and 23 out of 182 cases\(^2\), indicating that this disease is a serious condition with a poor prognosis. Its poor prognosis has often been reported in case reports and case-series. The age of death ranges from immediately after birth to 15 years old, and about 80% die in infancy (<1 year after birth).

Among case reports, we found a report on an infant who successfully self-defecated and self-urinated at the age of 1 year and 10 months\(^3\) and another report on an infant who successfully achieved a normal intake at the age of 2 years and 6 months.\(^4\) The physical and mental development of children with MMIHS has been reported to be delayed in one report\(^5\) and normal in another.\(^3\) Two reports have described patients starting school under home parenteral nutrition.\(^5, 6\)

**References**

**CQ7-3: What is the prognosis of chronic idiopathic intestinal pseudo-obstruction (CIIP)?**

**Recommendation:** The actual prognosis of CIIP developed in childhood is not poor; however, adequate nutritional support and intestinal stoma care are required for a long time in many cases. The functional prognosis of CIIP is poor.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>A (Strong)</th>
<th>B (Moderate)</th>
<th>C (Weak)</th>
<th>D (Very weak)</th>
</tr>
</thead>
</table>

**Commentary**

In Japan, out of 62 cases of children with CIPO, only 4.8% (3 out of 62 cases) died of enteritis or sepsis, and the prognosis of children CIPO seems to be relatively good. However, long-term central venous nutrition management is required for life support, and their quality of life is accordingly limited.

In a questionnaire survey of 45 cases at 1 to 21 years of age, 38% of the cases depended on parenteral nutrition, 17% on enteral nutrition via tube, and 4% on parenteral nutrition with enteral nutrition via tube. In other case series and case reports, many patients depended on parenteral nutrition, and their functional prognosis was poorer than that of healthy people.

The physical development was reported to be normal at 2\(^1\) and 8 years of age.\(^2\)

Regarding school and work, situations of CIPO patients to be equivalent to those of healthy people in three out of four cases\(^3\), and another showed that schooling was equivalent in two out of three cases; in one case, however, the patient was in a class for handicapped children.\(^4\)

**References**


### VII. Planning after public release

#### 1. Organization after public release

<table>
<thead>
<tr>
<th>Name of organization</th>
<th>Actions after public release</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline steering committee</td>
<td>The representative of this guideline steering committee shall belong to the Department of Pediatric Surgery, Faculty of Medical Sciences, Kyushu University. This guideline is planned to be revised five years after public release, and the organization for the revision group will be re-organized mainly by the Department of Pediatric Surgery, Faculty of Medical Sciences, Kyushu University. When the committee recognizes the need to modify the recommendation statements substantially, it will reconvene the guideline development group, announce a temporary stop of the usage or revision on the website after discussion, and conduct a complete revision. The expiration of the guideline will be discussed with the guideline development management office and the guideline development group.</td>
</tr>
<tr>
<td>Guideline development group</td>
<td>The group will publicly release this guideline on the homepages of the research partner institutions. When revision is required, it will be reported to the steering committee for discussion. Furthermore, when a revision is conducted in five years, the members will answer the steering committee's call to cooperate for the organization of the revision committee.</td>
</tr>
<tr>
<td>SR team</td>
<td>This team will be broken up at the completion of this guideline. However, when this guideline is revised in the future, the team members will cooperate with the revision group to provide as much advice as possible based on their experience in the guideline development.</td>
</tr>
</tbody>
</table>

#### 2. Introduction

| Creation of summary version | The detailed version will be published in research reports and distributed to major institutions. The practical version will be published as a book so that it may be utilized in daily clinical practice. |
| Proactive use of wide range of information media | The practical version will be released for free (on the Japanese Society of Pediatric Surgeons homepage, the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition homepage, Minds homepage, this guideline’s management office homepage, Research partner institutions’ homepage). Furthermore, media outlets, such as newspapers, magazines, and the Internet, will be used to increase the public recognition. |
| Promoting and inhibiting factors for the effective use of the clinical practice guideline | (Promoting factors) Increase in public recognition, establishment of a family association, establishment of a social security system, and consolidation of cases (Inhibiting factors) Conventional medical practices |

#### 3. Evaluation of effectiveness

<table>
<thead>
<tr>
<th>Evaluation method</th>
<th>Specific policies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retrospective study</td>
<td>A nationwide survey on the short and long-term outcomes of the cases after the public release of this guideline is to be conducted, and the outcomes will be reexamined using historical controls.</td>
</tr>
<tr>
<td>Prospective study</td>
<td>Standardization of treatments based on this guideline and a prospective, multi-center study to evaluate the effectiveness are to be conducted.</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>

4. Revision

<table>
<thead>
<tr>
<th>Items</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Period of implementation</td>
<td>Revision is expected five years later (2021).</td>
</tr>
<tr>
<td>Method of implementation</td>
<td>The guideline steering committee will organize a guideline revision group. However, if no financial support from related medical societies or the Research Project on Measures for Intractable Diseases of Ministry of Health, Labour and Welfare is obtained, reexamination is required.</td>
</tr>
<tr>
<td>Organization of implementation</td>
<td>The guideline steering committee of this guideline and the guideline development group will cooperate to reorganize a guideline revision group.</td>
</tr>
</tbody>
</table>